<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 28, 1996
-------------
PERSEPTIVE BIOSYSTEMS, INC.
______________________________________________________________
(Exact name of registrant as specified in its charter)
Delaware
_____________________________________________________
(State or other jurisdiction of incorporation)
0-20032 04-2987616
___________________________ _________________________
(Commission File Number) (IRS Employer Id. No.)
500 Old Connecticut Path Framingham, MA 01701
___________________________________________________________
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code:
(508) 383-7700
______________
<PAGE>
Item 5. Other Events.
------------
Effective June 28, 1996 (the "Closing Date"), PerSeptive Biosystems,
Inc. (the "Company") and ChemGenics Pharmaceuticals Inc., a Delaware corporation
located in Cambridge, Massachusetts ("ChemGenics"), completed the transactions
contemplated by a Master Agreement, dated as of May 7, 1996 (the "Master
Agreement"), between the Company and ChemGenics. Pursuant to the terms of the
Master Agreement, the Company transferred certain assets and employees of the
Company's drug discovery program and agreed to license under a related License
Agreement, dated June 28, 1996 (the "License Agreement"), between the Company
and ChemGenics, on a non-exclusive basis, the Company's technology in the field
of drug discovery to ChemGenics in exchange for 9,792,679 shares (the "Shares")
of common stock, $.001 par value per share (the "ChemGenics Common Stock"), of
ChemGenics, which is equal to forty percent (40%) of the fully diluted capital
stock of ChemGenics as of the date of the Master Agreement. Of such Shares,
979,268 shares (the "Earnout Shares") were issued to the Company as an earnout
payment for services, equipment use and supplies for a period of three (3) years
following the Closing Date. If any of the services, equipment use and supplies
are not provided by the Company during such three-year period in accordance with
a related Consulting and Interim Services Agreement, dated June 28, 1996 (the
"Consulting and Interim Services Agreement"), between the Company and
ChemGenics, the Company will forfeit certain of the Earnout Shares in accordance
with a formula set forth in the Consulting and Interim Services Agreement. In
addition, the Company was issued a warrant to purchase, for a period of four
years from the Closing Date, 4,896,335 shares (the "Warrant Shares") of
ChemGenics Common Stock at $5.00 per share.
Under the License Agreement, ChemGenics obtained a world-wide, royalty-
free, non-exclusive license to the Company's and the Company's affiliates'
patented and unpatented technology, in each case for use in drug discovery only
as set forth in the License Agreement.
As contemplated by the Master Agreement and in addition to the License
Agreement and Consulting and Interim Services Agreement, the Company and
ChemGenics have entered into a number of other related agreements dated as of
the Closing Date, including an agreement for use of a portion of the Company's
Framingham facility, a Confidentiality and Non-Competition Agreement, a
Standstill and Registration Rights Agreement providing the Company with certain
piggy-back and demand registration rights of the Shares and Warrant Shares and a
Voting Agreement providing for the election of nominees of the Company to the
Board of Directors of ChemGenics, subject to certain conditions.
Item 7. Financial Statements and Exhibits
---------------------------------
(c) Exhibits.
---------
Exhibit No. Exhibit
----------- -------
2 Master Agreement, dated as of May 7, 1996, between
ChemGenics Pharmaceuticals a d/b/a of Myco
Pharmaceuticals Inc.
-2-
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
PERSEPTIVE BIOSYSTEMS, INC.
By: /s/ Noubar B. Afeyan
-------------------------------
Noubar B. Afeyan
Chief Executive Officer
Dated: July 9, 1996
-3-
<PAGE>
Exhibit Index
Exhibit
Number Description
- ------ -----------
2 Master Agreement, dated as of May 7, 1996, between
ChemGenics Pharmaceuticals a d/b/a of Myco Pharmaceuticals Inc.
-4-
<PAGE>
EXHIBITS AND SCHEDULES OMITTED IN ACCORDANCE
WITH ITEM 601(b)(2) OF REGULATION S-K
EXHIBITS
- --------
Exhibit 1.03(A)(ii) Form of License Agreement
Exhibit 1.03(C)(i) Terms of Consulting and Interim Services Agreement
Exhibit 1.03(C)(ii) Terms of Sub-Lease Agreement
Exhibit 1.03(C)(iii) Terms of Confidentiality and Non-Competition Agreement
Exhibit 1.03(C)(iv) Terms of Standstill and Registration Rights Agreement
Exhibit 1.03(C)(v) Terms of Voting Agreement
Exhibit 4.02 Confidentiality Agreement (Pre-Closing)
Exhibit 6.06 Form of Opinion of PerSeptive's Counsel
Exhibit 7.06 Form of Opinion of ChemGenics' Counsel
SCHEDULES
- ---------
Schedule 1.01(b) Drug Discovery Program Assets
Schedule 1.02 Assumed Liabilities
Schedule 2.06 Drug Discovery Program Liabilities
Schedule 2.07 Absence of Adverse Change
Schedule 2.09 Litigation
Schedule 2.12 Certain Employees
Schedule 2.13 Employee Benefits
Schedule 2.17 Environmental Compliance
Schedule 2.19 Outstanding Commitments
Schedule 3.06 Financial Statements
Schedule 3.08 Transactions with Affiliates
Schedule 3.12 Capitalization
Schedule 3.17 Environmental Permits
Schedule 3.19 Certain Agreements
PerSeptive Biosystems, Inc. will furnish supplementally a copy of any
omitted exhibit or schedule to the Securities and Exchange Commission upon
request, provided, however that PerSeptive Biosystems, Inc. may request
confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of
1934, as amended, for any schedule or exhibit so furnished.
-5-
<PAGE>
EXHIBIT 2
---------
================================================================================
MASTER AGREEMENT
between
ChemGenics Pharmaceuticals
a d/b/a of
Myco Pharmaceuticals Inc.
and
PerSeptive Biosystems, Inc.
May 7, 1996
================================================================================
<PAGE>
INDEX TO EXHIBITS
EXHIBIT 1.03(A)(ii) - Form of License Agreement
EXHIBIT 1.03(C)(i) - Terms of Consulting and Interim Services Agreement
EXHIBIT 1.03(C)(ii) - Terms of Sub-Lease Agreement
EXHIBIT 1.03(C)(iii) - Terms of Confidentiality and Non-Competition Agreement
EXHIBIT 1.03(C)(iv) - Terms of Standstill and Registration Rights Agreement
EXHIBIT 1.03(C)(v) - Terms of Voting Agreement
EXHIBIT 4.02 - Confidentiality Agreement (Pre-Closing)
EXHIBIT 6.06 - Form of Opinion of PerSeptive's Counsel
EXHIBIT 7.06 - Form of Opinion of ChemGenics' Counsel
INDEX TO SCHEDULES
SCHEDULE 1.01(b) - Drug Discovery Program Assets
SCHEDULE 1.02 - Assumed Liabilities
SCHEDULE 2.06 - Drug Discovery Program Liabilities
SCHEDULE 2.07 - Absence of Adverse Change
SCHEDULE 2.09 - Litigation
SCHEDULE 2.12 - Certain Employees
SCHEDULE 2.13 - Employee Benefits
SCHEDULE 2.17 - Environmental Compliance
SCHEDULE 2.19 - Outstanding Commitments
SCHEDULE 3.06 - Financial Statements
SCHEDULE 3.08 - Transactions with Affiliates
SCHEDULE 3.12 - Capitalization
SCHEDULE 3.17 - Environmental Permits
SCHEDULE 3.19 - Certain Agreements
-i-
<PAGE>
MASTER AGREEMENT
This Master Agreement (this "Agreement") is entered into this 7th day
of May, 1996 by and among Myco Pharmaceuticals Inc. d/b/a ChemGenics
Pharmaceuticals, a Delaware corporation, ("ChemGenics"), and PerSeptive
Biosystems, Inc., a Delaware corporation ("PerSeptive").
WHEREAS, PerSeptive is engaged in the business of developing
technology and equipment used and useful in the making, measuring, processing
and delivery of biomolecules, including in the area of drug discovery;
WHEREAS, ChemGenics is a drug research and development company engaged
in the business of discovering, developing and commercializing novel treatments
for diseases, primarily through its expertise in drug discovery;
WHEREAS, PerSeptive desires to enter into a license and sell, license
or otherwise transfer to ChemGenics certain assets, projects and activities of
PerSeptive relating to drug discovery activities and efforts (the "Drug
Discovery Program") and to allow certain employees of PerSeptive who have worked
principally in the Drug Discovery Program to dedicate their full business time
to ChemGenics (the "Employees"); and, as set forth herein, to become employed by
ChemGenics under certain circumstances; and
WHEREAS, ChemGenics desires to acquire substantially all of the
assets, projects and activities of PerSeptive relating principally to the Drug
Discovery Program (other than administrative and financial aspects thereof) and
to utilize the services of the Employees, subject to the terms and conditions
provided in this Agreement and the Exhibits hereto.
NOW, THEREFORE, in consideration of the premises and the mutual
covenants contained in this Agreement, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties, intending to be legally bound, agree as follows:
ARTICLE I
---------
PURCHASE AND SALE OF ASSETS
---------------------------
SECTION 1.01 Transfer of Assets. (A) Upon the terms and subject to
------------------
the conditions set forth in this Agreement, at the Closing PerSeptive shall
sell, license, assign or transfer, as the case may be, to ChemGenics, and
ChemGenics will purchase and accept from PerSeptive, free and clear of all
claims, charges, liens, contracts, rights, options, security interests,
mortgages, encumbrances and restrictions whatsoever (collectively, "Claims"),
except as otherwise expressly set forth herein, all of the following assets,
projects and activities of PerSeptive (hereinafter, the "Transferred Assets"):
<PAGE>
(a) a world-wide, royalty-free, irrevocable, non-exclusive license to
PerSeptive's and its affiliates' presently existing and future patented and
unpatented technology, including access to prototype equipment, in each case for
use in drug discovery only as set forth in the License Agreement (defined
below);
(b) the equipment, supplies and other assets of the Drug Discovery
Program set forth on Schedule 1.01(b); the equipment set forth on
----------------
Schedule 1.01(b) shall be subject to certain restrictions contained in the
- ----------------
Consulting and Interim Services Agreement (defined below); and
(c) up to $500,000 of supplies of a type manufactured by PerSeptive or
of which PerSeptive is a distributor during the three year period following the
Closing; such supplies shall be valued based upon PerSeptive's actual cost of
acquisition or fully burdened cost of manufacture and shall be delivered to
ChemGenics from time to time in accordance with the Consulting and Interim
Services Agreement (defined below).
PerSeptive shall transfer the Transferred Assets to ChemGenics
pursuant to those documents and instruments set forth in Sections 1.03(A) and
1.03(C) below, and such other documents and instruments as ChemGenics or its
counsel may reasonably request.
B. Consideration for the Transferred Assets. In consideration for
----------------------------------------
the License Agreement and the transfer of the Transferred Assets, upon the terms
and subject to the conditions set forth in this Agreement, on the Closing Date,
ChemGenics shall issue to PerSeptive an aggregate of 9,792,679 shares (the
"Shares") of ChemGenics' common stock, $.001 par value per share (the "Common
Stock"). Of such Shares, 979,268 shares shall be issued to PerSeptive as an
earnout payment (the "Earnout Shares") for services, equipment use, supplies and
other PerSeptive assets for a period of three (3) years following the Closing
Date, as more fully set forth in the Consulting and Interim Services Agreement.
If any of the services, equipment, supplies and other PerSeptive assets are not
provided during such three-year period in accordance with the terms of the
Consulting and Interim Services Agreement, PerSeptive shall forfeit certain of
the Earnout Shares in accordance with the formula set forth in the Consulting
and Interim Services Agreement. PerSeptive shall be deemed to have earned the
Earnout Shares unless ChemGenics provides to PerSeptive a written notice of
failure to provide required services, equipment, supplies or other assets, and
PerSeptive fails to cure such failure within such period of time following the
notice, as more fully set forth in the Consulting and Interim Services
Agreement. The number of Earnout Shares subject to forfeiture shall decrease by
one-third (1/3) on each anniversary of the Closing Date, in accordance with the
following schedule:
<TABLE>
<CAPTION>
PERIOD SHARES SUBJECT TO FORFEITURE
------ ----------------------------
<S> <C>
From the Closing Date until
the 1st Anniversary Date 979,268
From 1st Anniversary Date
to 2nd Anniversary Date 652,844
</TABLE>
- 2 -
<PAGE>
<TABLE>
<S> <C>
From 2nd Anniversary Date
to 3rd Anniversary Date 326,422
After 3rd Anniversary Date 0
</TABLE>
In further consideration for the transfer of the Transferred Assets,
PerSeptive shall receive a warrant (the "Warrant"), to purchase 4,896,335 shares
of Common Stock at a price of $5.00 per share. The Warrant will be for a term
of four years from the Closing and will adjust for stock splits, stock dividends
and similar capital transactions and shall contain other customary terms and
conditions satisfactory to the parties.
PerSeptive may cause the Shares, the Warrant or the Common Stock issued
upon exercise of the Warrant to be transferred to one of its wholly-owned
subsidiaries, provided that PerSeptive shall retain 100% of the ownership and
--------
voting control of such subsidiary as long as such subsidiary holds the Shares,
the Warrant or shares of Common Stock issued upon exercise thereof.
SECTION 1.02 Assumption of Liabilities. The only obligations and
-------------------------
liabilities to be assumed by ChemGenics in connection with its acquisition of
the Transferred Assets (the "Assumed Liabilities") are the obligations and
liabilities specifically listed on Schedule 1.02. Except for the Assumed
-------------
Liabilities in the amount and to the extent provided in this Section, ChemGenics
shall not assume or be responsible for any liabilities or obligations to the
extent they arise from the operation of the Drug Discovery Program or to the
utilization of the Transferred Assets prior to the Closing, and PerSeptive shall
indemnify, defend, and hold ChemGenics harmless from all of such obligations and
liabilities. PerSeptive shall not assume any obligations and liabilities of
ChemGenics whatsoever.
SECTION 1.03 Closing. Subject to the satisfaction or waiver of each of
-------
the conditions set forth in Articles VI and VII of this Agreement, the closing
of the transactions contemplated by this Agreement (the "Closing") shall take
place at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., One
Financial Center, Boston, Massachusetts at 10 o'clock a.m. (Boston,
Massachusetts time), three business days following the termination of the
waiting period for the HSR Act (as defined below), or if later, the date on
which all closing conditions are satisfied or waived, or such other location,
date and time as may be agreed upon by the parties (such date and time being
called the "Closing Date"). At the Closing:
A. PerSeptive shall deliver or cause to be delivered to ChemGenics,
at the Closing or at such other location as ChemGenics shall specify, the
following:
(i) The Bill of Sale, transferring certain of the Transferred
Assets to ChemGenics, in the form reasonably satisfactory to the parties;
(ii) The License Agreement, licensing PerSeptive's drug discovery
technology and future developments to ChemGenics, in the form attached hereto as
Exhibit 1.03(A)(ii);
- -------------------
- 3 -
<PAGE>
(iii) The certificates required by Sections 6.03 and 6.04;
(iv) The opinion of counsel required by Section 6.06;
(v) A copy of the resolutions of PerSeptive certified by its
Secretary, authorizing and approving the execution, delivery and performance of
this Agreement and the transactions contemplated hereby and the acts of the
officers and employees of PerSeptive in carrying out the terms and provisions
hereof;
(vi) All of the books, data, documents, instruments and other
records relating principally to the Transferred Assets or Drug Discovery Program
(the "Documents") (or access thereto in the case of financial and other
documents which PerSeptive is required to retain) including without limitation
copies, if requested by ChemGenics, of the licenses, patents, patent
applications and permits identified in the Schedules to this Agreement and the
License Agreement and originals of all laboratory notebooks and other notes and
records relating principally to PerSeptive's drug discovery-related intellectual
property, provided, that the Documents shall be delivered to ChemGenics on the
--------
Closing either at ChemGenics' address specified in Section 10.01 or at the
Facility (as defined below); and
(vii) Executed copies of the ancillary documents listed in
Section 1.03(C) below.
B. ChemGenics shall deliver or cause to be delivered to PerSeptive,
at the Closing or at such other location as PerSeptive shall specify, the
following:
(i) The Shares;
(ii) The Warrant;
(iii) The Assumption Agreement, in the form reasonably
satisfactory to the parties;
(iv) The certificates required by Sections 7.03 and 7.04;
(v) The opinion of counsel required by Section 7.06;
(vi) A copy of the resolutions of ChemGenics certified by its
Secretary, authorizing and approving the execution, delivery and performance of
this Agreement, the exhibits hereto and the transactions contemplated hereby and
the acts of the officers and employees of ChemGenics in carrying out the terms
and provisions hereof; and
(vii) Executed copies of the ancillary documents listed in
Section 1.03(C) below.
C. The parties shall deliver or cause to be delivered:
- 4 -
<PAGE>
(i) The Consulting and Interim Services Agreement, certain
terms of which are attached hereto as Exhibit 1.03(C)(i), and as described in
------------------
Section 8.02;
(ii) The Sub-Lease Agreement for a portion of PerSeptive's
Framingham facility, certain terms of which are attached hereto as
Exhibit 1.03(C)(ii), and as described in Section 8.03, subject to obtaining the
- -------------------
landlord's consent; or, in lieu thereof, evidence satisfactory to ChemGenics
that it will have satisfactory use of such premises or equivalent premises on
equivalent terms for up to five employees of ChemGenics (other than the
Employees) through the date of the IPO referred to in Section 8.08 or the
earlier termination or rescission of this Agreement pursuant to the terms
hereof;
(iii) The Confidentiality and Non-Competition Agreement, certain
terms of which are attached hereto as Exhibit 1.03(C)(iii), and as described in
--------------------
Section 4.09;
(iv) The Standstill and Registration Rights Agreement, certain
terms of which are attached hereto as Exhibit 1.03(C)(iv), and as described in
-------------------
Section 8.04;
(v) The PBIO Voting Agreement, certain terms of which are
attached hereto as Exhibit 1.03(C)(v), pursuant to which nominees of PerSeptive
------------------
are to be elected to the Board of Directors of ChemGenics; and
(vi) Such further documents, resolutions, certificates and
instruments as any party or its counsel reasonably requests to facilitate the
consummation of the transactions contemplated hereby.
ARTICLE II
----------
REPRESENTATIONS AND WARRANTIES OF PERSEPTIVE
--------------------------------------------
As an inducement to ChemGenics to enter into this Agreement and to
consummate the transactions contemplated hereby, PerSeptive hereby represents
and warrants to ChemGenics as follows:
SECTION 2.01 Organization and Qualification. PerSeptive is a corporation
------------------------------
duly organized, validly existing and in good standing under the laws of the
jurisdiction of its incorporation and is duly qualified to transact business as
a foreign corporation and is in good standing in the Commonwealth of
Massachusetts being the only jurisdiction in which the nature of the Drug
Discovery Program or the character of the properties owned or leased by
PerSeptive and used principally in the Drug Discovery Program requires such
qualification and in which the failure to so qualify would have a material
adverse effect on PerSeptive.
SECTION 2.02 Corporate Power and Authority. PerSeptive has the corporate
-----------------------------
power and authority to own and hold its properties and to carry on its business.
PerSeptive has the corporate
- 5 -
<PAGE>
power and authority to execute, deliver and perform this Agreement and the other
documents and instruments contemplated hereby. The execution, delivery and
performance of this Agreement and the documents contemplated hereby and the
consummation of the transactions contemplated hereby and thereby have been duly
authorized and approved by PerSeptive. This Agreement, and each of the other
agreements, documents and instruments to be executed and delivered by PerSeptive
have been duly executed and delivered by, and constitute the legal, valid and
binding obligation of, PerSeptive enforceable against PerSeptive in accordance
with their terms, subject to bankruptcy and other laws of general application
affecting the rights and remedies of creditors and subject to general principles
of equity which may limit the availability of remedies.
SECTION 2.03 Validity, Etc. Neither the execution and delivery of this
--------------
Agreement and the other documents and instruments contemplated hereby, the
consummation of the transactions contemplated hereby or thereby, nor the
performance of this Agreement and such other agreements in compliance with the
terms and conditions hereof and thereof will (i) conflict with PerSeptive's
certificate of incorporation or bylaws, (ii) violate or conflict with any
judgment, decree, order, statute or regulation applicable to PerSeptive,
(iii) violate, conflict with or result in a breach, default or termination or
give rise to any right of termination, cancellation or acceleration of the
maturity of any payment date of any of the obligations of PerSeptive or increase
or otherwise affect the obligations of PerSeptive under any law, rule,
regulation or any judgment, decree, order, governmental permit, license or order
or any of the terms, conditions or provisions of any mortgage, indenture, note,
trust agreement, license agreement or other instrument or obligation related to
the Transferred Assets or to PerSeptive's ability to consummate the transactions
contemplated hereby or thereby, except for such defaults (or rights of
termination, cancellation or acceleration) as to which requisite waivers or
consents have been obtained in writing and provided to ChemGenics, (iv) violate
any order, writ, injunction, decree, statute, rule or regulation applicable to
PerSeptive or (v) result in the creation of any Claim upon the Transferred
Assets.
SECTION 2.04 No Governmental Consent. Except for the filing of any notice
-----------------------
prior or subsequent to the Closing that may be required under applicable state
and/or federal securities laws (which, if required of PerSeptive, shall be filed
on a timely basis by PerSeptive), and except for any consent or approval which
may be required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976
(the "HSR Act"), no authorization, consent, approval, license, exemption of or
filing or registration with any court or governmental department, commission,
board, bureau, agency or instrumentality, domestic or foreign, is or will be
necessary for, or in connection with, the execution and delivery by PerSeptive
of this Agreement, for the delivery of the Transferred Assets, or for the
performance by PerSeptive of its obligations under this Agreement and the other
agreements and instruments contemplated hereby.
SECTION 2.05 Financial Statements. PerSeptive has previously furnished or
--------------------
made available to ChemGenics its (i) Annual Report on Form 10-K for the fiscal
year ended September 30, 1995 (the "Form 10-K"), (ii) all proxy statements
relating to PerSeptive's meetings of stockholders held or to be held since
September 30, 1995 and (iii) all other reports filed by PerSeptive with the
Securities and Exchange Commission ("SEC") under the Securities Exchange Act of
1934, as amended (the Exchange Act") since September 30, 1995. As of their
respective dates, such reports complied in all material respects with applicable
SEC requirements and did not
- 6 -
<PAGE>
contain any untrue statement of material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein, in
light of the circumstances in which they were made, not misleading.
SECTION 2.06 Absence of Undisclosed Liabilities. Except as and to the
----------------------------------
extent of the amounts specifically reflected or reserved against in the balance
sheet dated September 30, 1995 (or the notes thereto) included in the Form 10-K
(the "PerSeptive Balance Sheet") and listed on Schedule 2.06 (the "Drug
-------------
Discovery Program Liabilities") PerSeptive does not have any material
liabilities or obligations relating to the Drug Discovery Program of any nature
whatsoever, due or to become due, accrued, absolute, contingent or otherwise,
except for liabilities and obligations incurred in the ordinary course of
business and consistent with past practice. PerSeptive does not know of, and
has no reason to know of, any basis for the assertion against PerSeptive of any
material liability or obligation relating to the Drug Discovery Program other
than the Drug Discovery Program Liabilities or incurred in the ordinary course
of business and consistent with past practice since the date of PerSeptive
Balance Sheet.
SECTION 2.07 Absence of Adverse Change; Conduct of Drug Discovery Program.
------------------------------------------------------------
Since September 30, 1995, there has been no material adverse change in the Drug
Discovery Program, the assets utilized therein, or the personnel conducting of
such Drug Discovery Program, and there is no condition or development or
contingency of any kind existing or in prospect which, so far as reasonably can
be foreseen by PerSeptive, may result in any such material adverse change.
Without limiting the foregoing, except as disclosed on Schedule 2.07, since
-------------
September 30, 1995 there has not been, occurred or arisen: (i) any damage,
destruction or loss to any Transferred Asset (whether or not covered by
insurance) that, individually or in the aggregate, would have a material adverse
effect on the Drug Discovery Program or prospects of the Drug Discovery Program;
(ii) any general increase in any compensation or benefits payable to the
Employees other than normal merit increases; or (iii) any commitment (contingent
or otherwise) to do any of the foregoing.
SECTION 2.08 Taxes. ChemGenics shall have no liability for any taxes of
-----
any kind or nature related to the ownership or operation of the Transferred
Assets or the ownership or operation of the Drug Discovery Program prior to the
Closing Date. PerSeptive has not taken or failed to take any action which could
create any tax lien on any of the Transferred Assets.
SECTION 2.09 Litigation. Except as set forth on Schedule 2.09, there is
---------- -------------
no (a) action, suit, claim, proceeding or investigation pending or, to the best
of PerSeptive's knowledge, threatened against or affecting PerSeptive (whether
or not PerSeptive is a party or prospective party thereto), at law or in equity,
or before or by any federal, state, municipal or other governmental department,
commission, board, bureau, agency or instrumentality, domestic or foreign, (b)
arbitration proceeding relating to PerSeptive or (c) governmental inquiry
pending or, to the best of PerSeptive's knowledge, threatened against or
involving PerSeptive, (i) relating to the Transferred Assets, the Drug Discovery
Program or the transactions contemplated hereby or (ii) in which a decision
adverse to PerSeptive would materially adversely affect the value of the
Transferred Assets as contemplated hereby and, to the best of PerSeptive's
knowledge, there is no basis for any of the foregoing. PerSeptive has not
received any opinion or memorandum or legal advice from legal counsel to the
effect that it is exposed, from a legal standpoint, to any liability or
disadvantage
- 7 -
<PAGE>
which may be material to the Transferred Assets, the Drug Discovery Program or
the transactions contemplated hereby. There are no outstanding orders, writs,
judgments, injunctions or decrees of any court, governmental agency or
arbitration tribunal against, involving or affecting the Transferred Assets, the
Drug Discovery Program or the transactions contemplated hereby, and there are no
facts or circumstances which may result in institution of any action, suit,
claim or legal, administrative or arbitration proceeding or investigation
against, involving or affecting the Transferred Assets, the Drug Discovery
Program or the transactions contemplated hereby. PerSeptive is not in default
with respect to any order, writ, injunction or decree known to or served upon it
from any court or of any federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality, domestic or
foreign, which might relate to the Transferred Assets, the Drug Discovery
Program or the transactions contemplated hereby. There is no action or suit by
PerSeptive or its affiliates pending or threatened against others relating to
the Transferred Assets, the Drug Discovery Program or the transactions
contemplated hereby.
SECTION 2.10 Compliance with Law. PerSeptive is not subject to any
-------------------
judgment, order, writ, injunction, or decree that materially adversely affects,
individually or in the aggregate, the businesses, operations, properties, assets
or condition (financial or otherwise) of the Drug Discovery Program. PerSeptive
has complied with and is not in material default under, all laws, ordinances,
legal requirements, rules, regulations and orders applicable to the Drug
Discovery Program, or the operations, properties, assets, products and services
of the Drug Discovery Program. There is no existing law, rule, regulation or
order, and PerSeptive is not aware of any proposed law, rule, regulation or
order, whether federal or state, which would prohibit or materially restrict
ChemGenics from, or otherwise materially adversely affect ChemGenics in,
conducting the Drug Discovery Program in the manner previously conducted.
SECTION 2.11 Labor and Employee Relations. PerSeptive is not a party to
----------------------------
or bound by any collective bargaining agreement with any labor organization,
group or association covering the Employees or any other Employee of PerSeptive
located at the Facility, and PerSeptive has no knowledge of any attempt to
organize the Employees or any other Employee of PerSeptive located at the
Facility by any person, unit or group seeking to act as their bargaining agent.
There are no pending or threatened charges (by Employees, their representatives
or governmental authorities) of unfair labor practices or of employment
discrimination or of any other wrongful action with respect to any aspect of
employment of any person employed or formerly employed by PerSeptive in the Drug
Discovery Program. No union representation elections relating to Employees or
any other Employee of PerSeptive located at the Facility have been scheduled by
any governmental agency or authority, no organizational effort is being made
with respect to any of such Employees or any other Employee of PerSeptive
located at the Facility, and there is no investigation of PerSeptive's
employment policies or practices by any governmental agency or authority pending
or, to the best of PerSeptive's knowledge, threatened. PerSeptive is not
currently, and has not within the last three years been, involved in labor
negotiations with any unit or group seeking to become the bargaining unit for
any Employees or any other Employee of PerSeptive located at the Facility.
PerSeptive has not experienced any work stoppages during the last three years
and, to the best of PerSeptive's knowledge, no work stoppage is planned.
- 8 -
<PAGE>
SECTION 2.12 Certain Employees. Set forth in Schedule 2.12 is a list of
----------------- -------------
the names of PerSeptive's employees and consultants principally engaged in the
technical aspects of the Drug Discovery Program which PerSeptive will make
available to ChemGenics pursuant to the Consulting and Interim Services
Agreement and to which ChemGenics will make offers of employment pursuant to
Section 8.01 hereof, together with the title or job classification of each such
person and the base annual and the total compensation paid to each such person
by PerSeptive in fiscal year 1995 and anticipated to be paid in fiscal year
1996. None of such persons has an employment agreement or understanding,
whether oral or written, with PerSeptive which is not terminable on notice by
PerSeptive without cost or other liability to PerSeptive or ChemGenics. No
person listed on Schedule 2.12 has indicated that he or she intends to terminate
-------------
his or her employment with PerSeptive or seek a material change in his or her
duties or status.
SECTION 2.13 Employee Benefits. Set forth on Schedule 2.13 is a list of
----------------- -------------
all pension, profit sharing, retirement, deferred compensation, stock purchase,
stock option, incentive, bonus, vacation, severance, disability,
hospitalization, medical insurance, life insurance, fringe benefit, welfare and
other employee benefit plans, programs or arrangements to which Employees may be
entitled. Such benefits are the same benefits afforded other employees of
PerSeptive at similar levels of experience.
PerSeptive will maintain the benefits listed on Schedule 2.13 (as such
-------------
benefits may change generally for PerSeptive's employees) in full force and
effect through the Closing Date, and thereafter with respect to events occurring
while the Employees were employed by PerSeptive. ChemGenics shall have no
obligation of any kind or nature for any compensation or benefits of any kind or
nature of the employees or consultants of PerSeptive for service rendered while
such Employees or consultants were employed by PerSeptive, including, without
limitation, vacation or sick time for which PerSeptive will compensate
ChemGenics or the Employees, as appropriate.
Each "Employee Welfare Benefit Plan" (as defined in Section 3(1) of the
Employee Retirement Income Security Act of 1974, as amended ("ERISA")) covering
any present or former employee of PerSeptive who has worked in the Drug
Discovery Program subject to the requirements of the Consolidated Omnibus Budget
Reconciliation Act of 1985 ("COBRA") has complied with all requirements for
continuation coverage under group health benefit plans under COBRA and there are
no claims against PerSeptive for a failure or alleged failure to comply with the
COBRA continuation requirements.
Each employee plan which is subject to ERISA conforms to, and its operation
and administration are in compliance with, all applicable requirements of ERISA.
There are no actions, suits or claims pending (other than routine claims for
benefits) or threatened against any employee plan or against the assets of any
employee plan.
SECTION 2.14 Tangible Properties. Schedule 1.01(b) contains a true and
------------------- ----------------
complete list of all tangible personal property owned by or leased to PerSeptive
and used principally in the Drug Discovery Program (the "Tangible Personal
Property") which is being transferred to ChemGenics pursuant to this Agreement.
Such Tangible Personal Property constitutes all of the instruments and other
assets having an original estimated list value in excess of $10,000, and
substantially all of the
- 9 -
<PAGE>
other Tangible Personal Property used by PerSeptive principally in the Drug
Discovery Program (including, without limitation, all of the tangible assets
utilized by the Employees in the Drug Discovery Program). Except as shown on
Schedule 1.01(b), PerSeptive has good and marketable title free and clear of all
- ----------------
Claims to the Tangible Personal Property listed as owned by PerSeptive. With
respect to Tangible Personal Property leased by PerSeptive as lessee, all
leases, conditional sale contracts, franchises or licenses pursuant to which
PerSeptive may hold or use (or permit others to hold or use) such Tangible
Personal Property are valid and in full force and effect, and there is not under
any of such instruments any existing default or event of default or event which
with notice or lapse of time or both would constitute such a default, and the
transfer of PerSeptive's interest in any Tangible Personal Property hereunder
shall not constitute an event of default or default or an event which with
notice or lapse of time or both would constitute such a default under such
leases, conditional sale contracts, franchises or licenses, except for the
requirement of consents set forth in Schedule 1.01(b), and except where such an
----------------
actual or potential default has been consented to or waived. PerSeptive's
possession and use of such property has not been disturbed and no claim has been
asserted against PerSeptive adverse to its rights in such leasehold interests.
Each item of Tangible Personal Property, whether owned or leased, is in
good operating condition and repair and has been reasonably maintained in
accordance with industry practices. The only liability of PerSeptive for
failure of the representation in the preceding sentence shall be the repair or
replacement of the affected item of Tangible Personal Property.
SECTION 2.15 Acquisition by PerSeptive of Transferred Assets from
----------------------------------------------------
PerSeptive Technologies II Corporation ("PTC-II"). PTC-II has no and never had
- -------------------------------------------------
any material tangible assets. The License Agreement conveys to ChemGenics the
right to use all intellectual property rights utilized by PTC-II in connection
with the Drug Discovery Program. PerSeptive shall indemnify ChemGenics with
respect to any claim, action, judgment, damage, fee or expense arising out of
the formation and operation of PTC-II and the offer and sale of securities of
PTC-II, the acquisitions of the units of PTC-II through the exchange offer set
forth in the Proxy Statement/Prospectus dated February 8, 1996, including,
without limitation, the acquisition of PTC-II Property as a result of such
exchange offer, and the transfer of the PTC-II Property hereunder. This
provision shall be in addition to, and in no way limit, any other representation
or warranty hereunder which might relate to PTC-II.
SECTION 2.16 Leased Premises. The Drug Discovery Program has been
---------------
principally conducted at the facility at 500 Old Connecticut Path, Framingham,
Massachusetts (the "Facility"). The lease covering the Facility is in full
force and effect (there existing no default under the lease which, with the
lapse of time or notice or otherwise, would entitle the lessor to terminate the
same), conveys the leased real estate purported to be conveyed thereunder and is
enforceable by PerSeptive. PerSeptive has the right to use the Facility in
accordance with the terms of such lease free and clear of all Claims or other
interests or rights of third parties, except those which do not or would not
have a material adverse effect on the Facility as used in the Drug Discovery
Program. To the best of PerSeptive's knowledge, the Facility is structurally
sound, adequately maintained and is in good condition and repair (except for
immaterial matters) consistent with the uses to which it is presently being put
or intended to be put, and the Facility's structure, improvements, fixtures and
uses conform to any and all applicable federal, state and local laws, building,
health
- 10 -
<PAGE>
and safety and other ordinances, laws, rules and regulations, except where
nonconformance would not materially restrict the conduct of the Drug Discovery
Program as presently conducted. There is no violation of any material covenant,
restriction or other agreement or understanding, oral or written, affecting or
relating to title or use of the Facility. There are no pending condemnation or
similar proceedings or assessments affecting the Facility, nor to PerSeptive's
best knowledge is any such condemnation or assessment contemplated by any
governmental authority. No real estate owned by PerSeptive is used in the Drug
Discovery Program.
SECTION 2.17 Environmental Matters.
---------------------
(a) Environmental Substance Liability. To the best of PerSeptive's
---------------------------------
knowledge, no event has occurred or condition exists or operating practice is
being employed that could give rise to material liability with respect to the
Facility or the Drug Discovery Program, either at the present time or in the
future, for any losses, liabilities, damages (whether consequential or
otherwise), settlements, penalties, interest and expenses (including any such
liability on account of the right of any governmental or private entity or
person, and including closure expenses, costs of assessment, containment, or
removal (other than transportation or disposal of materials required to be
transported or disposed of in the ordinary course of business, remedial work, or
monitoring) arising under any presently enacted federal, state, or local
statute, or any regulation that has been promulgated pursuant thereto, or common
law, as a result of or in connection with, or alleged to be as a result of or in
connection with, the following:
(i) the handling, storage, use, transportation or disposal of
any Substances (as hereinafter defined) in or near or from the Facility, by
PerSeptive or its predecessors;
(ii) the handling, storage, use, transportation or disposal of
any Substances by PerSeptive or its predecessors which Substances were a
product, by-product or otherwise resulted from the operation of the Drug
Discovery Program conducted by or on behalf of PerSeptive or its predecessors;
(iii) any intentional or unintentional emission, discharge or
release of any Substances in or near or from the Facility into or upon the air,
surface water, ground water or land or any disposal, handling, manufacturing,
processing, distribution, use, treatment, or transport of such Substances in or
near or from the Facility by or on behalf of PerSeptive or its predecessors; or
(iv) the presence of any toxic or hazardous building materials
(including but not limited to asbestos or similar substances) in the Facility,
including but not limited to the inclusion of such materials in the exterior and
interior walls, floors, ceilings, tile, insulation or any other portion of the
Facility.
As used in this Section 2.17, the term "Substances" shall mean any
pollutant, hazardous substance, hazardous material, hazardous waste or toxic
waste, as defined in any presently enacted federal, state or local statute or
any regulation that has been promulgated pursuant thereto.
- 11 -
<PAGE>
(b) Environmental Permits. To the best of PerSeptive's knowledge
---------------------
after due investigation, PerSeptive has obtained and holds all registrations,
permits, licenses, and approvals issued by or on behalf of any federal, state or
local government body or agency ("Environmental Permits"), that are required in
connection with the discharge or emission of Substances (as hereinabove defined)
from the Drug Discovery Program at the Facility or the generation, treatment,
storage, transportation, or disposal of any such Substances. Such Environmental
Permits, which are described in Schedule 2.17 in connection with the operation
-------------
of the Drug Discovery Program, are currently effective and sufficient for the
ownership and operation of the Drug Discovery Program as currently conducted,
the failure to have would have a material adverse effect on the Drug Discovery
Program.
PerSeptive represents, covenants and warrants to and agrees with
ChemGenics, as of the date of this Agreement and as of the time of Closing, as
follows:
(i) To the best of PerSeptive's knowledge after due
investigation, PerSeptive and the operation of the Drug Discovery Program at the
Facility are, and at the time of Closing shall be, in compliance with all
applicable laws, rules, regulations, orders, ordinances, judgments and decrees
of all governmental authorities (federal, state, and local). Except as set forth
in Schedule 2.17, PerSeptive is not aware of, nor has PerSeptive received notice
-------- ----
of, any past, present or future events, conditions, circumstances, activities,
practices, incidents, actions or plans of PerSeptive or PerSeptive's
predecessors, either collectively, individually or severally, which may
interfere with or prevent continued compliance, or which may give rise to any
common law or legal liability, or otherwise form the basis of any claim, action,
suit, proceeding, hearing, or investigation, based on or related to the
disposal, storage, handling, manufacture, processing, distribution, use,
treatment, or transport, or the emission, discharge, release or threatened
release into the environment, of any Pollutant.
(ii) The Facility has not been listed or proposed for listing
on the National Priorities List established by the United States Environmental
Protection Agency, the List of Confirmed Disposal Sites and Locations To Be
Investigated established by the Commonwealth of Massachusetts Department of
Environmental Quality Engineering, or any other such list.
(iii) PerSeptive has obtained all material permits, licenses and
other authorizations which are required with respect to operation of the Drug
Discovery Program at the Facility under federal, state and local laws or
otherwise relating to pollution or protection of the environment. Except as set
forth in Schedule 2.17, PerSeptive is in full compliance with all terms and
-------- ----
conditions of such required permits, licenses and authorizations, and is also in
full compliance with all other limitations, restrictions, conditions, standards,
prohibitions, requirements, obligations, schedules, and timetables contained in
those laws or provisions or contained in any regulation, code, plan, order,
decree, judgment, notice or demand letter issued, entered, promulgated or
approved thereunder and applicable to the operation of the Drug Discovery
Program at the Facility.
SECTION 2.18 Insurance. PerSeptive is, and will be through the Closing
---------
and during the Consulting and Interim Services Agreement, adequately insured
with responsible insurers in respect
- 12 -
<PAGE>
of its properties, assets and businesses against risks normally insured against
by companies in similar lines of business under similar circumstances.
SECTION 2.19 Outstanding Commitments. Schedule 2.19 sets forth a
----------------------- -------------
description of all existing contracts, agreements, commitments, licenses and
franchises which involve more than $10,000 in consideration over the remaining
term of the contract, agreement, commitment, license or franchise, other than
agreements which relate only incidentally to the Drug Discovery Program and
which are not reasonably required in the ongoing conduct of the Drug Discovery
Program (collectively "Agreements"), whether written or oral, relating to the
Drug Discovery Program. PerSeptive has delivered or made available to
ChemGenics true, correct and complete copies of all of the Agreements specified
on Schedule 2.19 which are in writing, and Schedule 2.19 contains an accurate
------------- -------------
and complete description of all Agreements which are not in writing. PerSeptive
has paid in full all amounts due as of the date hereof under each Agreement
identified in Schedule 2.19 and as of the Closing Date will have satisfied in
-------------
full all of its liabilities and obligations thereunder due in the ordinary
course of business prior to the Closing (it being understood that this
representation shall not prevent PerSeptive from withholding payment in good
faith based on a dispute with respect to its obligation to make payment,
provided that the foregoing shall not be deemed to imply that ChemGenics shall
have any liability therefore, and provided such nonpayment does not materially
adversely affect the Transferred Assets or the Drug Discovery Program). All of
the Agreements described in Schedule 2.19 are in full force and effect.
-------------
PerSeptive and each other party thereto have performed all the obligations
required to be performed by them to date, have received no notice of default and
are not in default (with due notice or lapse of time or both) under any
Agreement. PerSeptive has no present expectation or intention of not fully
performing all its obligations under each Agreement, and PerSeptive has no
knowledge of any breach or anticipated breach by the other party to any contract
or commitment to which PerSeptive is a party. None of such Agreements has been
terminated, no notice has been given by any party thereto of any alleged default
by any party thereunder, and PerSeptive is not aware of any intention or right
of any party to default another party to any such Agreement. There exists no
actual or, to the knowledge of PerSeptive, threatened termination, cancellation
or limitation of the business relationship of PerSeptive with any party to any
such Agreement.
SECTION 2.20 Intellectual Property. The representations of PerSeptive in
---------------------
Section 4.1.7 of the form of License Agreement attached hereto as
Exhibit 1.03(A)(ii) are hereby incorporated by reference as if set forth fully
herein. PerSeptive has the right to utilize the intellectual property rights it
has utilized in the conduct of the Drug Discovery Program, all of which will be
duly and validly transferred or licensed to ChemGenics pursuant to this
Agreement or the License Agreement, as the case may be, without violation of any
agreement to which PerSeptive is a party or is bound, except such rights which
are not material to the Drug Discovery Program and which are licensed to
PerSeptive and which PerSeptive is prohibited from licensing to ChemGenics.
SECTION 2.21 Proprietary Information of Third Parties. No third party has
----------------------------------------
claimed or, to the best knowledge of PerSeptive, has reason to claim that
PerSeptive or any person employed by or affiliated with PerSeptive has in
connection with the Drug Discovery Program (a) violated or may be violating any
of the terms or conditions of PerSeptive's or such person's employment, non-
competition or non-disclosure agreement with such third party, (b) disclosed or
may be
- 13 -
<PAGE>
disclosing or utilized or may be utilizing any trade secret or proprietary
information or documentation of such third party, or (c) interfered or may be
interfering in the employment relationship between such third party and any of
its present or former employees. No third party has requested information from
PerSeptive which suggests that such a claim might be contemplated. To
PerSeptive's best knowledge, no person employed by or affiliated with PerSeptive
has employed or proposes to employ any trade secret or any information or
documentation proprietary to any former employer and, no person employed by or
affiliated with PerSeptive has violated any confidential relationship which such
person may have had with any third party, in connection with the development,
manufacture or sale of any product or proposed product or the development or
sale of any service or proposed service of the Drug Discovery Program, and
PerSeptive has no reason to believe there will be any such employment or
violation. To the best of PerSeptive's knowledge, none of the execution or
delivery of this Agreement, or the carrying on of the Drug Discovery Program as
officers, employees or agents by any officer, director, employee or consultant
of the Drug Discovery Program, or the conduct or proposed conduct of the Drug
Discovery Program, will conflict with or result in a breach of the terms,
conditions or provisions of or constitute a default under any contract, covenant
or instrument under which any such person is obligated.
SECTION 2.22 Disclosure. All documents and schedules delivered or to be
----------
delivered by or on behalf of PerSeptive in connection with this Agreement and
the transactions contemplated hereby are true, complete and correct in all
material respects. Neither this Agreement, nor any Schedule or Exhibit to this
Agreement contains any untrue statement of a material fact or omits a material
fact necessary to make the statements contained herein or therein, in light of
the circumstances in which made, not misleading.
SECTION 2.23 Purchase For Investment. PerSeptive is acquiring the Shares,
-----------------------
the Warrant and Common Stock issuable upon exercise of the Warrant, and the
Earnout Shares, if any, for investment for its own account and not with a view
to the distribution or public offering thereof within the meaning of the
Securities Act of 1933, as amended (the "Securities Act"). PerSeptive
understands that the Shares, the Warrant and Common Stock issuable upon exercise
of the Warrant, have not been registered under the Securities Act or any state
securities or "blue sky" laws and may not be sold or transferred without such
registration or an exemption therefrom. PerSeptive consents to the placement of
a legend on its certificate for the Shares and on the Warrant stating that such
securities have not been registered and setting forth the restrictions on
transfer contemplated hereby and by the Standstill and Registration Rights
Agreement. PerSeptive is sufficiently experienced in financial and business
matters to be capable of evaluating the risk of investment in the Shares and the
Warrant, and to make an informed decision relating thereto. PerSeptive has the
financial capability for making the investment, can afford a complete loss of
the investment, and the investment is a suitable one for PerSeptive. PerSeptive
is an Accredited Investor as defined in Regulation D under the Securities Act.
Prior to the execution and delivery of this Agreement, PerSeptive has been
furnished with all information which it deems necessary to evaluate the merits
and risks of the Shares and the Warrant and has had the opportunity to ask
questions of and receive answers from representatives of ChemGenics regarding
ChemGenics, the Shares and the Warrant.
- 14 -
<PAGE>
ARTICLE III
-----------
REPRESENTATIONS AND WARRANTIES OF CHEMGENICS
--------------------------------------------
As an inducement to PerSeptive to enter into this Agreement and to
consummate the transactions contemplated hereby, ChemGenics hereby represents
and warrants to PerSeptive as follows:
SECTION 3.01 Organization. ChemGenics is a corporation duly organized,
------------
validly existing and in good standing under the laws of the jurisdiction of its
incorporation and is duly qualified to transact business as a foreign
corporation and is in good standing in the Commonwealth of Massachusetts, such
jurisdiction being the only jurisdiction in which the character of the
properties owned or leased by ChemGenics requires such qualification and in
which the failure to so qualify would have a material adverse effect on
ChemGenics.
SECTION 3.02 Corporate Power and Authority. ChemGenics has the corporate
-----------------------------
power and authority to own and hold its properties and to carry on its business.
ChemGenics has the corporate power and authority to execute, deliver and perform
this Agreement and the other documents and instruments contemplated hereby. The
execution, delivery and performance of this Agreement and the documents
contemplated hereby and the consummation of the transactions contemplated hereby
and thereby have been duly authorized and approved by ChemGenics. This
Agreement, and each of the other agreements, documents and instruments to be
executed and delivered by ChemGenics have been duly executed and delivered by,
and constitute the legal, valid and binding obligation of, ChemGenics
enforceable against ChemGenics in accordance with their terms, subject to
bankruptcy and other laws of general application affecting the rights and
remedies of creditors and subject to general principles of equity which may
limit the availability of remedies.
SECTION 3.03 Validity, Etc. Neither the execution and delivery of this
-------------
Agreement and the other documents and instruments contemplated hereby, the
consummation of the transactions contemplated hereby or thereby, nor the
performance of this Agreement and such other agreements in compliance with the
terms and conditions hereof and thereof will (i) conflict with ChemGenics'
certificate of incorporation or bylaw, (ii) violate or conflict with any
judgment, decree, order, statute or regulation applicable to ChemGenics,
(iii) violate, conflict with or result in a breach, default or termination or
give rise to any right of termination, cancellation or acceleration of the
maturity of any payment date of any of the obligations of ChemGenics or increase
or otherwise affect the obligations of ChemGenics under any law, rule,
regulation or any judgment, decree, order, governmental permit, license or order
or any of the terms, conditions or provisions of any mortgage, indenture, note,
trust agreement, license agreement or other instrument or obligation related to
ChemGenics or to ChemGenics' ability to consummate the transactions contemplated
hereby or thereby, except for such defaults (or rights of termination,
cancellation or acceleration) as to which requisite waivers or consents have
been obtained in writing and provided to PerSeptive or (iv) violate any order,
writ, injunction, decree, statute, rule or regulation applicable to ChemGenics.
SECTION 3.04 No Governmental Consent. Except for the filing of any notice
-----------------------
prior or subsequent to the Closing that may be required under applicable state
and/or federal securities laws
- 15 -
<PAGE>
(which, if required, shall be filed on a timely basis), and except for any
consent or approval which may be required under the HSR Act, no authorization,
consent, approval, license, exemption of or filing or registration with any
court or governmental department, commission, board, bureau, agency or
instrumentality, domestic or foreign, is or will be necessary for, or in
connection with, the execution and delivery by ChemGenics of this Agreement, for
the offer, issue, sale, execution or delivery of the Shares, and the Warrant, or
for the performance by ChemGenics of its obligations under this Agreement and
the other agreements and instruments contemplated hereby.
SECTION 3.05 Litigation. There is no (a) action, suit, claim, proceeding
----------
or investigation pending or, to the best of ChemGenics' knowledge, threatened
against or affecting ChemGenics (whether or not ChemGenics is a party or
prospective party thereto), at law or in equity, or before or by any federal,
state, municipal or other governmental department, commission, board, bureau,
agency or instrumentality, domestic or foreign, (b) arbitration proceeding
relating to ChemGenics or (c) governmental inquiry pending or, to the best of
ChemGenics' knowledge, threatened against or involving ChemGenics in which a
decision adverse to ChemGenics would materially adversely affect ChemGenics and,
to the best of ChemGenics' knowledge, there is no basis for any of the
foregoing. There are no outstanding orders, writs, judgments, injunctions or
decrees of any court, governmental agency or arbitration tribunal, and there are
no facts or circumstances which may result in institution of any action, suit,
claim or legal, administrative or arbitration proceeding or investigation which
might prevent ChemGenics from entering into and performing this Agreement and
the other documents and instruments contemplated hereby. ChemGenics is not in
default with respect to any order, writ, injunction or decree known to or served
upon it from any court or of any federal, state, municipal or other governmental
department, commission, board, bureau, agency or instrumentality, domestic or
foreign which might prevent ChemGenics from entering into and performing this
Agreement and the other documents and instruments contemplated hereby.
SECTION 3.06 Financial Statements. ChemGenics has previously furnished to
--------------------
PerSeptive, and attached hereto as Schedule 3.06 are audited financial
-------------
statements of ChemGenics from the years ended December 31, 1994 and 1995. All
such financial statements (the "ChemGenics Financial Statements") have been
prepared in accordance with generally accepted accounting principles
consistently applied and were prepared from the books and records of ChemGenics,
which books and records are complete and correct in all material respects.
ChemGenics Financial Statements fairly present the financial position of
ChemGenics as of the dates thereof and the results of its operations and cash
flows for the periods ended on the dates thereof. ChemGenics Financial
Statements reflect reserves appropriate and adequate for all known material
liabilities and reasonably anticipated losses as required by generally accepted
accounting principles. Since the date of ChemGenics Balance Sheet (defined
below), (a) there has been no change in the assets, liabilities or financial
condition of the assets of ChemGenics from that reflected in ChemGenics Balance
Sheet except for changes in the ordinary course of business consistent with past
practice and which have not been materially adverse and (b) none of the
business, prospects, financial condition, operations, property or affairs of
ChemGenics has been materially adversely affected by any occurrence or
development, individually or in the aggregate, whether or not insured against.
ChemGenics has disclosed to PerSeptive all material facts relating to the
preparation of ChemGenics Financial Statements, including the basis of
accounting for affiliated transactions.
- 16 -
<PAGE>
SECTION 3.07 Absence of Undisclosed Liabilities. Except as and to the
----------------------------------
extent of the amounts specifically reflected or reserved against in the balance
sheet dated December 31, 1995 (or the notes thereto) included in ChemGenics
Financial Statements (the "ChemGenics Balance Sheet") ChemGenics does not have
any material liabilities or obligations of any nature whatsoever, due or to
become due, accrued, absolute, contingent or otherwise, except for material
liabilities and obligations incurred in the ordinary course of business and
consistent with past practice. ChemGenics does not know of any basis for the
assertion against ChemGenics of any material liability or obligation not fully
reflected or reserved against in ChemGenics Balance Sheet or incurred in the
ordinary course of business and consistent with past practice since the date
thereof.
SECTION 3.08 Transactions with Affiliates. Except as set forth in
----------------------------
Schedule 3.08 there are no loans, leases, royalty agreements or other continuing
- -------------
transactions between (a) ChemGenics or, to ChemGenics' knowledge, any of its
customers or suppliers, and (b) any officer, employee, consultant or director of
ChemGenics or any Person owning five percent (5%) or more of the capital stock
of ChemGenics, or to ChemGenics' knowledge, any member of the immediate family
of such officer, employee, consultant, director or stockholder or any
corporation or other entity controlled by such officer, employee, consultant,
director or stockholder, or a member of the immediate family of such officer,
employee, consultant, director or stockholder.
SECTION 3.09 Investments in Other Persons. ChemGenics has not made any
----------------------------
loans or advances in excess of $100,000 in the aggregate to any Person which is
outstanding on the date of this Agreement, nor is it committed or obligated to
make any such loan or advance, nor does ChemGenics own any capital stock, assets
comprising the business of, obligations of, or any interest in, any Person.
ChemGenics does not have, and has not since its incorporation had, any
Subsidiaries.
SECTION 3.10 Absence of Adverse Change. Since December 31, 1995, there
-------------------------
has been no material adverse change in the business, financial condition,
operations or assets of ChemGenics. Since December 31, 1995 ChemGenics has
conducted its business in the ordinary course.
SECTION 3.11 Disclosure. All documents and schedules delivered or to be
----------
delivered by or on behalf of ChemGenics in connection with this Agreement and
the transactions contemplated hereby are true, complete and correct in all
material respects. Neither this Agreement, nor any Schedule or Exhibit to this
Agreement contains any untrue statement of a material fact or omits a material
fact necessary to make the statements contained herein or therein, in light of
the circumstances in which made, not misleading.
SECTION 3.12 Capitalization; Status of Capital Stock. ChemGenics has a
---------------------------------------
total authorized capitalization consisting of (i) 16,000,000 shares of Common
Stock, $.001 par value and (ii) 11,275,000 shares of preferred stock, $.01 par
value ("Preferred Stock"), of which 6,400,000 shares are designated as Series A
Convertible Preferred Stock, $.01 par value ("Series A Preferred Stock"),
1,100,000 shares are designated as Series B Convertible Preferred Stock, $.01
par value ("Series B Preferred Stock"), 775,000 shares are designated as Series
C Convertible Preferred Stock, $.01 par value ("Series C Preferred Stock"), and
3,000,000 shares are designated as Series D
- 17 -
<PAGE>
Preferred Stock, $.01 par value ("Series D Preferred Stock;" the Series A
Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D
Preferred Stock are collectively the "Preferred Stock"). 1,523,700 shares of
Common Stock are issued and outstanding, 6,150,732 shares of Series A Preferred
Stock are issued and outstanding, 1,063,366 shares of Series B Preferred Stock
are issued and outstanding, 767,739 shares of Series C Preferred Stock are
issued and outstanding and 3,000,000 shares of Series D Preferred Stock are
issued and outstanding. Each outstanding share of Preferred Stock is on the date
hereof convertible into one share of Common Stock. All the outstanding shares of
capital stock of ChemGenics have been duly authorized, and are validly issued,
fully paid and non-assessable. The Shares when issued and delivered in
accordance with the terms thereof, are duly authorized, validly issued, fully-
paid and non-assessable. The shares of Common Stock underlying the Warrant, when
issued and delivered in accordance with the terms of the Warrant, are duly
authorized, validly issued, and, assuming payment therefor in accordance with
the terms hereof, fully-paid and non-assessable. Except for 2,006,400 shares of
Common Stock that have been reserved for issuance upon exercise of stock
options, 177,083 shares of Series A Preferred Stock that have been reserved for
issuance upon exercise of warrants issued or to be issued to Comdisco, Inc. (the
"Comdisco Leasing Warrants"), the shares of Common Stock reserved for issuance
upon the conversion of the currently outstanding shares of Series A Preferred
Stock, Series B Preferred Stock, Series C Preferred Stock, Series D Preferred
Stock and upon the conversion of the shares of Series A Preferred Stock which
may be issued upon exercise of the Comdisco Leasing Warrants, no options,
warrants, subscriptions or purchase rights of any nature to acquire from
ChemGenics, or commitments of ChemGenics to issue, shares of capital stock or
other securities are authorized, issued or outstanding, nor is ChemGenics
obligated in any other manner to issue shares or rights to acquire any of its
capital stock or other securities except as contemplated by this Agreement. None
of ChemGenics' outstanding securities or authorized capital stock are subject to
any rights of redemption, repurchase, rights of first refusal, preemptive rights
or other similar rights, whether contractual, statutory or otherwise, for the
benefit of ChemGenics, or to ChemGenics' knowledge, any stockholder, or any
other Person, except pursuant hereto or as set forth on Schedule 3.12, and to
-------------
the knowledge of ChemGenics, except as set forth on Schedule 3.12, there are no
-------------
voting agreements regarding its securities. Except as set forth in
Schedule 3.12, there are no restrictions on the transfer of shares
- -------------
of capital stock of ChemGenics other than those imposed by relevant federal and
state securities laws and as otherwise contemplated by this Agreement.
SECTION 3.13 Absence of Certain Developments. ChemGenics is not a party
-------------------------------
to any written or material oral contract or instrument or other corporate
restriction which individually or in the aggregate is reasonably likely to
adversely affect the business, prospects, financial condition, operations,
Intellectual Property Rights, property or affairs of ChemGenics.
SECTION 3.14 Certain Agreements of Officers and Employees. To ChemGenics'
--------------------------------------------
knowledge, no officer, employee or consultant of ChemGenics is, or is now or
will be at the Closing, in violation of any material term of any employment
contract, patent disclosure agreement, proprietary information agreement, non-
competition agreement, non-solicitation agreement, confidentiality agreement, or
any other similar contract or agreement or any restrictive covenant, relating to
the right of any such officer, employee, or consultant to be employed or engaged
by ChemGenics because of the nature of the business conducted or to be conducted
by ChemGenics or
- 18 -
<PAGE>
relating to the use of trade secrets or proprietary information of others which
is reasonably likely to have a material adverse effect on ChemGenics.
SECTION 3.15 Compliance. ChemGenics is in compliance in all material
----------
respects with the terms and provisions of its Restated Certificate of
Incorporation and By-laws, each as amended and/or restated to date, and with the
terms and provisions of all mortgages, indentures, leases, agreements and other
instruments by which it is bound or to which it or any of its properties or
assets are subject where noncompliance would have a material adverse affect on
the business, assets, operations, or financial condition of ChemGenics.
ChemGenics is in compliance in all respects with, and has not defaulted under,
all judgments, decrees, governmental orders, laws, statutes, rules or
regulations by which it is bound or to which it or any of its properties or
assets are subject where noncompliance or default would have a material adverse
affect on the business, assets, operations, or financial condition of
ChemGenics.
SECTION 3.16 Title to Assets, Patents. ChemGenics has good and
------------------------
merchantable title to its tangible assets. ChemGenics enjoys peaceful and
undisturbed possession under all leases under which it is operating, and all
said leases are valid and subsisting and in full force and effect in all
material respects.
ChemGenics owns or has a valid right to use the intellectual property
rights being used to conduct its business; and to ChemGenics' knowledge the
conduct of its business does not conflict with or infringe upon the intellectual
property rights of others in any manner which is reasonably anticipated to have
a material adverse effect on ChemGenics. No claim is pending or to ChemGenics'
knowledge threatened against ChemGenics and/or, to ChemGenics' knowledge, its
officers, employees and consultants to the effect that any such right owned or
licensed by ChemGenics is invalid or subject to any claim of infringement.
Within 15 days of the date hereof, ChemGenics will provide PerSeptive with a
list of its patents and patent applications.
ChemGenics has taken reasonable measures to protect and preserve the
security, confidentiality and value of its intellectual property rights. All
employees and consultants of ChemGenics involved in the design, review,
evaluation or development of intellectual property rights have executed
nondisclosure and assignment of inventions agreements. ChemGenics has not
received notice of, and to the best of ChemGenics' knowledge after reasonable
investigation, there are no claims that ChemGenics' intellectual property rights
or the use or ownership thereof by ChemGenics infringes, violates or conflicts
with any such right of any third party.
SECTION 3.17 Environmental and Safety Laws. To the best of ChemGenics'
-----------------------------
knowledge after due investigation, it is not in violation of any applicable
statute, law or regulation relating to the environment or occupational safety
and health which would have a material adverse effect on ChemGenics.
To the best of ChemGenics' knowledge after due investigation, ChemGenics
has obtained and holds all registrations, permits, licenses, and approvals
issued by or on behalf of any federal, state or local government body or agency
("Environmental Permits"), that are required in connection with the discharge or
emission of Substances at its premises or the generation,
- 19 -
<PAGE>
treatment, storage, transportation, or disposal of any such Substances or
otherwise for the operation of ChemGenics' business. Such Environmental Permits,
which are described in Schedule 3.17, are currently effective and sufficient for
-------------
the ownership and operation of its business as currently conducted, the failure
to have would have a material adverse effect on ChemGenics.
SECTION 3.18 Insurance. ChemGenics is insured with responsible insurers
---------
in respect of its properties, assets and businesses against risks normally
insured against by companies in similar lines of business under similar
circumstances.
SECTION 3.19 Certain Agreements. Within fifteen days from the date hereof
------------------
Chemgenics will provide PerSeptive with a list of all existing contracts,
agreements, commitments, licenses and franchises which are material to the
operation of ChemGenics business. ChemGenics has previously delivered or made
available to PerSeptive true, correct and complete copies of all such
agreements.
ChemGenics is not a party to any agreement which would prevent its
execution, delivery or performance of this Agreement. Except as set forth in
Schedule 3.19, ChemGenics is not a party to any agreement the terms of which
- -------------
require ChemGenics to disclose to the other party thereto the proprietary
information transferred to ChemGenics pursuant to this Agreement, or to
sublicense, assign or otherwise grant any license or other rights which
ChemGenics will obtain pursuant to this Agreement.
ARTICLE IV
----------
COVENANTS OF PERSEPTIVE
-----------------------
PerSeptive covenants and agrees with ChemGenics as follows:
SECTION 4.01 Best Efforts Cooperation. PerSeptive shall use its
------------------------
reasonable best efforts in good faith to perform and fulfill all conditions and
obligations to be fulfilled or performed by it hereunder, to the end that the
transactions contemplated hereby will be fully and timely consummated.
SECTION 4.02 Access. Until the Closing, PerSeptive shall give ChemGenics,
------
its attorneys, accountants and other authorized representatives complete access,
upon reasonable notice and at reasonable times, to PerSeptive's offices,
properties, employees, products, technology, business and financial records,
contracts, business plans, budgets and projections, agreements and commitments
and other documents and information concerning the Drug Discovery Program and
persons employed by or doing business with PerSeptive in connection with the
Drug Discovery Program. For three (3) years following the Closing, PerSeptive
shall provide ChemGenics with reasonable access to any and all records relating
to the Drug Discovery Program which remain in the possession of accountants,
attorneys and other parties. In order that ChemGenics may have full opportunity
to make such examination and investigation as it may desire of the business and
affairs of PerSeptive in connection with the Drug Discovery Program, PerSeptive
will furnish
- 20 -
<PAGE>
ChemGenics and its representatives during such period with all such information
as such representatives may reasonably request and cause the respective
officers, employees, consultants, agents, accountants and attorneys of
PerSeptive to cooperate fully with the representatives of ChemGenics in
connection with such review and examination and to make full disclosure to
ChemGenics of all material facts affecting PerSeptive's financial condition,
business operations, properties and prospects as each relate to the Drug
Discovery Program; provided, however, that ChemGenics will hold the documents
-------- -------
and information concerning PerSeptive and the Drug Discovery Program
confidential in accordance with the Confidentiality Agreement, as amended
April 23, 1996 in the form of Exhibit 4.02 between PerSeptive and ChemGenics
------------
dated October 25, 1996 (the "Confidentiality Agreement"), as amended as of
April 23, 1996.
SECTION 4.03 Properties, Business, Insurance. Until the Closing and
-------------------------------
during the term of the Consulting and Interim Services Agreement, PerSeptive
shall maintain with financially sound and reputable insurers, insurance against
such casualties and contingencies and of such types and in such amounts as is
customary for companies similarly situated.
SECTION 4.04 Compliance with Laws. PerSeptive shall conduct the Drug
--------------------
Discovery Program in all material respects in compliance with all applicable
laws, rules, regulations and orders.
SECTION 4.05 Actions Prior to Closing. PerSeptive shall conduct the Drug
------------------------
Discovery Program pending the Closing in a manner consistent with past practice.
Without limiting the generality of the foregoing, PerSeptive will not, except in
the ordinary and usual course of business, without the prior written consent of
ChemGenics do any of the following regarding the Transferred Assets or the Drug
Discovery Program: (i) make any acquisition or disposition of assets, (ii) enter
into any contract or release or relinquish any contract or other right, or
(iii) enter into or renew any employment agreement with any employees or
consultants or grant any increases in the compensation or benefits to, or agree
to pay any bonus, severance or termination payment or other special compensation
to any employees or consultants.
SECTION 4.06 Litigation. PerSeptive will promptly notify ChemGenics of
----------
any lawsuits, claims, proceedings or investigations which are threatened or
commenced against or by PerSeptive or its affiliates, or against any employee,
consultant or director of PerSeptive (i) relating to the Transferred Assets, the
Drug Discovery Program or the transactions contemplated hereby or (ii) in which
a decision adverse to PerSeptive would adversely affect the value of the
Transferred Assets or the Drug Discovery Program.
SECTION 4.07 Continued Effectiveness of Representations and Warranties.
---------------------------------------------------------
From the date hereof up to and including the Closing Date, (i) PerSeptive will
conduct the Drug Discovery Program in a manner such that the representations and
warranties contained herein shall continue to be true and correct on and as of
the Closing Date as if made on and as of the Closing Date, except for changes
and the consequences of events arising in the ordinary and usual course of
business after the date hereof and none of which would have an adverse effect on
the properties, assets, operations or condition (financial or otherwise) or
prospects of the Drug Discovery Program; and (ii) PerSeptive will advise
ChemGenics promptly in writing of any condition or circumstance
- 21 -
<PAGE>
occurring from the date hereof up to and including the Closing Date which could
cause any representations or warranty of PerSeptive to become untrue in any
material respect.
SECTION 4.08 No Negotiations. Until July 1, 1996, or the earlier
---------------
termination of this Agreement in accordance with its terms, neither PerSeptive
nor any of its affiliates, advisors, agents or investment bankers shall,
directly or indirectly, initiate discussions with, engage in negotiations with,
or provide any information to any corporation, partnership, person or other
entity or group involving the possible sale, directly or indirectly, transfer or
joint venture of any part of the Transferred Assets or the Drug Discovery
Program to any person or entity other than ChemGenics.
SECTION 4.09 Confidentiality and Non-Competition. At the Closing
-----------------------------------
PerSeptive will enter into a Confidentiality and Non-Competition Agreement (the
"Confidentiality and Non-Competition Agreement") containing the terms set forth
in Exhibit 4.09, and such other terms and conditions and otherwise in form and
------------
substance satisfactory to each party.
ARTICLE V
---------
COVENANTS OF CHEMGENICS
-----------------------
SECTION 5.01 Cooperation. ChemGenics shall use its reasonable best
-----------
efforts in good faith to perform and fulfill all conditions and obligations to
be fulfilled or performed by it hereunder to the end that the transactions
contemplated hereby will be fully and timely consummated.
SECTION 5.02 Access. Until the Closing, ChemGenics shall give PerSeptive,
------
its attorneys, accountants and other authorized representatives complete access,
upon reasonable notice and at reasonable times, to ChemGenics' offices,
properties, employees, products, technology, business and financial records,
contracts, business plans, budgets and projections, agreements and commitments
and other documents and information concerning ChemGenics and persons employed
by or doing business with ChemGenics. In order that PerSeptive may have full
opportunity to make such examination and investigation as it may desire of the
business and affairs of ChemGenics, ChemGenics will furnish PerSeptive and its
representatives during such period with all such information as such
representatives may reasonably request and cause the respective officers,
employees, consultants, agents, accountants and attorneys of ChemGenics to
cooperate fully with the representatives of ChemGenics in connection with such
review and examination and to make full disclosure to PerSeptive of all material
facts affecting ChemGenics' financial condition, business operations, properties
and prospects; provided, however, that PerSeptive will hold the documents and
-------- -------
information concerning ChemGenics confidential in accordance with the
Confidentiality Agreement.
SECTION 5.03 Litigation. ChemGenics will promptly notify PerSeptive of
----------
any lawsuits, claims, proceedings or investigations which are threatened or
commenced against or by ChemGenics or its affiliates, or against any employee,
consultant or director of ChemGenics.
- 22 -
<PAGE>
SECTION 5.04 Continued Effectiveness of Representations and Warranties.
---------------------------------------------------------
From the date hereof up to and including the Closing Date, (i) ChemGenics will
conduct its business in the ordinary course and a manner such that the
representations and warranties contained herein shall continue to be true and
correct on and as of the Closing Date as if made on and as of the Closing Date,
except for changes and the consequences of events arising in the ordinary and
usual course of business after the date hereof and none of which would have an
adverse effect on the properties, assets, operations or condition (financial or
otherwise) or prospects of the business of ChemGenics; and (ii) ChemGenics will
advise PerSeptive promptly in writing of any condition or circumstance occurring
from the date hereof up to and including the Closing Date which could cause any
representations or warranty of ChemGenics to become untrue in any material
respect.
SECTION 5.05 No Amendments. Except as contemplated by this Agreement
-------------
(including amendments to increase the number of shares of authorized Common
Stock of ChemGenics and to change ChemGenics' corporate name), from the date
hereof up to and including the Closing Date, ChemGenics will not amend its
Restated Certificate of Incorporation or By-laws, effect any recapitalization,
enter into any merger agreement, or sell or enter into any agreement regarding
the sale of, all or substantially all of its assets.
SECTION 5.06 Right of First Refusal; Percentage Maintenance.
----------------------------------------------
(a) Right of First Refusal. From and after the Closing, before ChemGenics
----------------------
shall issue, sell or exchange, agree or obligate itself to issue, sell or
exchange, or reserve or set aside for issuance, sale or exchange, any (i) shares
of Common Stock, (ii) any other equity security of ChemGenics, including without
limitation, shares of preferred stock, (iii) any convertible debt security of
ChemGenics, including without limitation, any debt security which by its terms
is convertible into or exchangeable for any equity security of ChemGenics, (iv)
any security of ChemGenics that is a combination of debt and equity, or (v) any
option, warrant or other right to subscribe for, purchase or otherwise acquire
any interest relating to such equity or debt security of ChemGenics, ChemGenics
shall, in each case, first offer to sell such securities (the "Offered
Securities") to PerSeptive that portion of the Offered Securities as the number
of shares of Common Stock then held by PerSeptive bears to the total number of
outstanding shares of capital stock of ChemGenics on a fully diluted basis, at a
price and on such other terms as shall have been specified by ChemGenics in
writing delivered to PerSeptive (the "Offer"), which Offer by its terms shall
remain open and irrevocable for a period of twenty (20) days from receipt of the
Offer.
(b) Notice of Acceptance. Notice of PerSeptive's intention to accept any
--------------------
Offer made pursuant to Section 5.06(a) shall be evidenced by a writing signed by
PerSeptive and delivered to ChemGenics prior to the end of the 20-day period of
such offer (the "Notice of Acceptance").
(c) Conditions to Acceptance and Purchase.
-------------------------------------
(i) Permitted Sales of Refused Securities. In the event that a Notice
-------------------------------------
of Acceptance is not given by PerSeptive in respect of all of the Offered
Securities, ChemGenics shall have ninety (90) days from the end of said 20-day
period to sell any such Offered Securities as to which a Notice of Acceptance
has not been given by PerSeptive (the "Refused Securities") to the
- 23 -
<PAGE>
person or persons specified in the Offer or to any other person who has a right
of first refusal to purchase ChemGenics' securities, but only upon terms and
conditions, including, without limitation, unit price and interest rates, which
are no more favorable, in the aggregate, to such other person or persons or less
favorable to ChemGenics than those set forth in the Offer.
(ii) Reduction in Amount of Offered Securities. In the event
-----------------------------------------
ChemGenics shall propose to sell less than all of the Refused Securities (any
such sale to be in the manner and on the terms specified in Section 5.06(c)(i)
above), then PerSeptive shall reduce the number of shares or other units of the
Offered Securities specified in its Notice of Acceptance to an amount which
shall be not less than the amount of the Offered Securities which PerSeptive
elected to purchase pursuant to Section 5.06(b) multiplied by a fraction,
(I) the numerator of which shall be the amount of Offered Securities which
ChemGenics actually proposes to sell, and (II) the denominator of which shall be
the amount of all Offered Securities. In the event that PerSeptive so elects to
reduce the number or amount of Offered Securities specified in its Notice of
Acceptance, ChemGenics may not sell or otherwise dispose of more than the
reduced amount of the Offered Securities until such securities have again been
offered to PerSeptive in accordance with Section 5.06(a).
(iii) Closing. Upon the closing, which shall include full payment to
-------
ChemGenics, of the sale to such other person or persons of all or less than all
the Refused Securities, PerSeptive shall purchase from ChemGenics, and
ChemGenics shall sell to PerSeptive, the number of Offered Securities specified
in the Notice of Acceptance, as reduced pursuant to Section 5.06(c)(ii) upon the
terms and conditions specified in the Offer. The purchase by PerSeptive of any
Offered Securities is subject in all cases to the preparation, execution and
delivery by ChemGenics and PerSeptive of a purchase agreement relating to such
Offered Securities reasonably satisfactory in form and substance to ChemGenics
and PerSeptive.
(d) Further Sale. In each case, any Offered Securities not purchased by
------------
PerSeptive or other person or persons in accordance with Section 5.06(c) may not
be sold or otherwise disposed of until they are again offered to PerSeptive
under the procedures specified in Sections 5.06(a)-(c).
(e) Termination of Right of First Refusal. The rights of PerSeptive under
-------------------------------------
this Section 5.06 shall terminate immediately prior to the effectiveness of, and
shall not apply to shares issued pursuant to, a registration statement filed by
ChemGenics with respect to an offering of its securities, but expressly
conditioned on the consummation of such offering.
(f) Exceptions. The rights of PerSeptive under this Section 5.06 shall not
----------
apply to:
(i) Common Stock issued as a stock dividend to holders of Common Stock
or upon any subdivision or combination of shares of Common Stock;
(ii) Preferred Stock issued as a dividend to holders of Preferred
Stock upon any subdivision or combination of shares of Preferred Stock, provided
--------
that the number of shares of Common Stock issuable upon conversion of the
preferred stock as a percentage of the total equity of ChemGenics shall remain
the same;
- 24 -
<PAGE>
(iii) the issuance of Common Stock upon exercise of the Warrant;
(iv) the issuance of Common Stock upon conversion of any Preferred
Stock or any other convertible securities of ChemGenics outstanding as of the
date hereof or issued in accordance with this Section 5.06;
(v) up to 3,000,000 shares of Common Stock, or options or warrants
exercisable therefor (including 2,006,400 options granted prior to and
outstanding on the date hereof pursuant to ChemGenics' 1992 Stock Option Plan),
issued on or after the date hereof to directors, officers, employees or
consultants of ChemGenics and any subsidiary (including members of ChemGenics'
Scientific Advisory Board) pursuant to any qualified or non-qualified stock
option plan or agreement, employee stock ownership plan, employee benefit plan,
stock purchase agreement, stock plan, stock restriction agreement, or consulting
agreement or such other options, warrants, equity arrangements, agreements or
plans in each case approved by two-thirds of the members of the Board of
Directors of ChemGenics;
(vi) up to 177,083 shares of Series A Preferred Stock issued pursuant
to the Comdisco Leasing Warrants, and shares of Common Stock issued upon
conversion of such shares;
(vi) shares of capital stock or options or warrants therefor, to be
issued to equipment leasing organizations in connection with any equipment
leasing arrangements to which ChemGenics is a party and which have been approved
by the Board of Directors; or
(vii) shares of capital stock issued in connection with a merger or
acquisition approved by the Board of Directors.
Each of the foregoing numbers shall be subject to equitable adjustment in
the event of any stock dividend, stock split, combination, reorganization,
recapitalization, reclassification or other similar event.
SECTION 5.07 Confidentiality and Non-Competition. At the Closing
-----------------------------------
ChemGenics will enter into the Confidentiality and Non-Competition Agreement.
ARTICLE VI
----------
CONDITIONS TO CHEMGENICS' OBLIGATIONS
-------------------------------------
The obligation of ChemGenics to issue and transfer the Shares on the
Closing Date and to consummate the other transactions contemplated hereby is
subject to the satisfaction, on or before the Closing Date, of the following
conditions each of which may be waived by ChemGenics in its sole discretion:
SECTION 6.01 No Material Adverse Economic Event. There shall not have
----------------------------------
occurred (i) any general suspension of trading in, or limitation on prices for,
or other extraordinary event
- 25 -
<PAGE>
affecting securities on the New York Stock Exchange, (ii) a declaration of a
banking moratorium or any suspension of payments in respect of banks in the
United States or (iii) any material limitation (whether or not mandatory) by any
governmental authority on, or any other event which might affect the extension
of credit by, lending institutions, or (iv) in the case of any of the foregoing
existing on the Closing Date a material acceleration or worsening thereof.
SECTION 6.02 Consents. All requisite governmental approvals and consents
--------
of third parties required to be received to prevent any license, permit or
agreement material to the Drug Discovery Program from terminating prior to its
scheduled termination, as a result of the consummation of the transactions
contemplated hereby, shall have been obtained, including, without limitation,
the expiration of any waiting period or the receipt of any consent or approval
which may be required under the HSR Act.
SECTION 6.03 Representations and Warranties True. All of the
-----------------------------------
representations and warranties of PerSeptive contained in this Agreement or in
any Schedules or other documents attached hereto or referred to herein or
delivered pursuant hereto or in connection with the transactions contemplated
hereby shall be true, correct and complete in all material respects on and as of
the date hereof and on and as of the Closing Date, as if made on and as of the
Closing Date. On the Closing Date, PerSeptive shall have executed and delivered
to ChemGenics a certificate, in form and substance satisfactory to ChemGenics
and its counsel, to such effect.
SECTION 6.04 Performance. PerSeptive shall have performed and complied
-----------
with all covenants and agreements contained herein required to be performed or
complied with by it prior to or at the Closing Date. PerSeptive shall have
executed and delivered to ChemGenics a certificate, in form and substance
satisfactory to ChemGenics and its counsel, in writing to such effect and to the
further effect that all of the conditions set forth in this Article VI have been
satisfied.
SECTION 6.05 No Adverse Change. No change shall have occurred or be
-----------------
threatened in the condition, properties, assets or liabilities of the Drug
Discovery Program, which has or is or is reasonably likely to frustrate the
essential purposes of this transaction.
SECTION 6.06 Opinion of Counsel. ChemGenics shall have received the
------------------
opinion of Samuel P. Hunt III, Esq., in substantially the form attached hereto
as Exhibit 6.06.
------------
SECTION 6.07 No Actions, Suits or Proceedings. As of the Closing Date, no
--------------------------------
action, suit, investigation or proceeding brought by any person, corporation,
governmental agency or other entity shall be pending or, to the knowledge of the
parties to this Agreement, threatened, before any court or governmental body
(i) to restrain, prohibit, restrict or delay, or to obtain damages or a
discovery order in respect of this Agreement or the consummation of the
transactions contemplated hereby, or (ii) which has had or may have a materially
adverse effect on the condition, financial or otherwise, or prospects of the
Drug Discovery Program. No order, decree or judgment of any court or
governmental body shall have been issued restraining, prohibiting, restricting
or delaying, the consummation of the transactions contemplated by this
Agreement. No insolvency proceeding of any character including without
limitation, bankruptcy, receivership, reorganization, dissolution or arrangement
with creditors, voluntary or involuntary, affecting PerSeptive shall be pending,
and
- 26 -
<PAGE>
PerSeptive shall not have taken any action in contemplation of, or which would
constitute the basis for, the institution of any such proceedings.
SECTION 6.08 Investigation Satisfactory. ChemGenics shall have reviewed
--------------------------
all of the Schedules, and shall be satisfied that (i) none of the information on
any Schedule (as they may be supplemented prior to the Closing) frustrates the
essential business purpose of the transaction contemplated hereby and (ii) that
the representations and warranties of PerSeptive are true and correct in all
material respects.
SECTION 6.09 Closing Documents. PerSeptive shall have delivered all of
-----------------
the resolutions, certificates, documents, ancillary agreements and instruments
required by this Agreement.
SECTION 6.10 Approval of ChemGenics' Stockholders and Preferred
--------------------------------------------------
Stockholders. The stockholders of ChemGenics shall have approved the requisite
- ------------
amendments to ChemGenics' Certificate of Incorporation and the holders of
ChemGenics' Preferred Stock shall have consented to the transactions
contemplated hereby as required under the terms of the Preferred Stock and
agreements executed in connection with the issuance thereof. ChemGenics will
seek to obtain such approvals and consents promptly following the execution of
this Agreement and will use best efforts to obtain such approval and consent on
or before May 10, 1996.
SECTION 6.11 Approval of ChemGenics and Its Counsel. All actions,
--------------------------------------
proceedings, consents, instruments and documents required to be delivered by, or
at the behest or direction of, PerSeptive hereunder or incident to its
performance hereunder, and all other related matters, shall be reasonably
satisfactory as to form and substance to ChemGenics and its counsel.
ARTICLE VII
-----------
CONDITIONS TO PERSEPTIVE'S OBLIGATIONS
--------------------------------------
The obligation of PerSeptive to transfer the Transferred Assets to
ChemGenics and to consummate the other transactions contemplated hereby is
subject to the satisfaction, on or before the Closing Date, of the following
conditions, each of which may be waived by PerSeptive in its sole discretion:
SECTION 7.01 No Material Adverse Economic Event. There shall not have
----------------------------------
occurred (i) any general suspension of trading in, or limitation on prices for,
or other extraordinary event affecting securities on the New York Stock
Exchange, (ii) a declaration of a banking moratorium or any suspension of
payments in respect of banks in the United States or (iii) any material
limitation (whether or not mandatory) by any governmental authority on, or any
other event which might affect the extension of credit by, lending institutions,
or (iv) in the case of any of the foregoing existing on the Closing Date a
material acceleration or worsening thereof.
SECTION 7.02 Consents. All requisite governmental approvals and consents
--------
of third parties required to be received to prevent any license, permit or
agreement material to the Drug
- 27 -
<PAGE>
Discovery Program from terminating prior to its scheduled termination, as a
result of the consummation of the transactions contemplated hereby, shall have
been obtained, including, without limitation, the expiration of any waiting
period or the receipt of any consent or approval which may be required under the
HSR Act.
SECTION 7.03 Representations and Warranties True. All of the
-----------------------------------
representations and warranties of ChemGenics contained in this Agreement or in
any Schedules or other documents attached hereto or referred to herein or
delivered pursuant hereto or in connection with the transactions contemplated
hereby shall be true, correct and complete in all material respects on and as of
the date hereof and on and as of the Closing Date, as if made on and as of the
Closing Date. On the Closing Date, ChemGenics shall have executed and delivered
to ChemGenics a certificate, in form and substance satisfactory to ChemGenics
and its counsel, to such effect.
SECTION 7.04 Performance. ChemGenics shall have performed and complied in
-----------
all material respects with all agreements contained herein required to be
performed or complied with by it prior to or at the Closing Date, and ChemGenics
shall have delivered a certificate to PerSeptive, in form and substance
satisfactory to PerSeptive and its counsel to such effect and to the further
effect that all of the conditions set forth in this Article VII have been
satisfied.
SECTION 7.05 No Adverse Change. No change shall have occurred or be
-----------------
threatened in the condition (financial or other) of ChemGenics, the results of
its operations, properties, assets, liabilities or businesses which has been or
is or is reasonably likely to be materially adverse to its operations,
properties, prospects, assets or condition (financial or other).
SECTION 7.06 Opinion of ChemGenics' Counsel. PerSeptive shall have
------------------------------
received from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., an opinion
dated the Closing Date, in substantially the form attached hereto as
Exhibit 7.06.
- ------------
SECTION 7.07 No Actions, Suits or Proceedings. As of the Closing Date, no
--------------------------------
action, suit, investigation or proceeding brought by any person, corporation,
governmental agency or other entity shall be pending or, to the knowledge of the
parties to this Agreement, threatened, before any court or governmental body to
restrain, prohibit, restrict or delay, or to obtain damages or a discovery order
in respect of this Agreement or the consummation of the transactions
contemplated hereby. No order, decree or judgment of any court or governmental
body shall have been issued restraining, prohibiting, restricting or delaying,
the consummation of the transactions contemplated by this Agreement. No
insolvency proceeding of any character including without limitation, bankruptcy,
receivership, reorganization, dissolution or arrangement with creditors,
voluntary or involuntary, affecting ChemGenics shall be pending, and ChemGenics
shall not have taken any action in contemplation of, or which would constitute
the basis for, the institution of any such proceedings.
SECTION 7.08 Investigation Satisfactory. PerSeptive shall have reviewed
--------------------------
all of the Schedules, and shall be satisfied that (i) none of the information on
any Schedule (as they may be supplemented prior to the Closing) frustrates the
essential business purpose of the transaction
- 28 -
<PAGE>
contemplated hereby and (ii) that the representations and warranties of
ChemGenics are true and correct in all material respects.
SECTION 7.09 Closing Documents. ChemGenics shall have delivered the
-----------------
Shares and all of the resolutions, certificates, documents, ancillary agreements
and instruments required by this Agreement.
SECTION 7.10 Approval of PerSeptive and Its Counsel. All actions,
--------------------------------------
proceedings, consents, instruments and documents required to be delivered by, or
at the behest or direction of, ChemGenics hereunder or incident to its
performance hereunder, and all other related matters, shall be reasonably
satisfactory as to form and substance to PerSeptive and its counsel.
SECTION 7.11 No Change of Control. There shall not have occurred between
--------------------
the date hereof and the Closing a transfer of all or substantially all of the
outstanding shares of capital stock of ChemGenics to parties other than
ChemGenics' existing stockholders or their affiliates.
SECTION 7.12 Name Change. Myco Pharmaceuticals Inc. shall have changed
-----------
its name to ChemGenics Pharmaceuticals Inc., or such other name as PerSeptive
shall approve.
SECTION 7.13 Chairman of the Board. Noubar B. Afeyan shall have been
---------------------
elected to serve as Chairman of the Board of ChemGenics and he or his designee
as a member of its Scientific Advisory Board.
ARTICLE VIII
------------
POST-CLOSING COVENANTS
----------------------
SECTION 8.01 Employee Matters.
----------------
(a) Immediately after the execution of this Agreement, PerSeptive shall
make available to ChemGenics each of the Employees, who will dedicate his or her
full business time to the Drug Discovery Program of ChemGenics and perform the
services reasonably requested by ChemGenics. The Employees shall remain
employees of PerSeptive until and subject to the Closing and ChemGenics shall
have no responsibility or obligation therefor and nothing contained herein shall
give the Employees any rights to employment by ChemGenics. Upon the Closing
ChemGenics shall reimburse PerSeptive for the salary, costs of benefits and
reimbursements for expenses incurred by such employees between the date hereof
and the Closing.
(b) Upon the Closing, ChemGenics will offer employment to each of the
Employees listed in Schedule 2.12, or any other person employed by PerSeptive
-------------
who may have been substituted for one of the Employees after the date hereof
with the consent of ChemGenics (a "Substitute Employee") at a salary level not
less than that in effect on the date hereof and with benefits comparable to
ChemGenics' employees similarly situated, and PerSeptive shall use its
reasonable best efforts to cause such persons to enter into employment or
consulting arrangements
- 29 -
<PAGE>
or agreements with ChemGenics (as ChemGenics shall designate), and ChemGenics
agrees to negotiate in good faith such arrangements or agreements; provided
--------
that, anything herein to the contrary notwithstanding, no provision of this
Section 8.01 shall create any third-party beneficiary rights in any person or
organization, including, without limitation, employees or former employees
(including any beneficiary or dependent thereof) of PerSeptive or any of its
affiliates, trustees, administrators, participants or beneficiaries of any
employee benefit plan, and no provision of this Section 8.01 shall create such
third-party beneficiary rights in any such person or organization in respect of
any benefits that might be provided, directly or indirectly, under any employee
benefit plan or arrangement, including the currently existing plans of
PerSeptive. PerSeptive and ChemGenics each agree to (a) use its reasonable best
efforts to effect the transfer of the designated Employees so as to prevent the
creation of any severance or termination penalties or benefits in respect of
such transfer and (b) cooperate with the filings, calculations and other actions
necessary to effect the transactions contemplated by this Section 8.01 and in
obtaining any governmental approvals required hereunder.
SECTION 8.02 Consulting and Interim Services. The parties shall perform
-------------------------------
their respective obligations under the Consulting and Interim Services
Agreement. In addition to the services of Employees set forth in Section 8.01,
PerSeptive shall provide to ChemGenics (i) from time to time for a period of
three years after the Closing Date up to $500,000 of supplies distributed or
manufactured by PerSeptive valued at fully burdened manufactured or actual
acquired cost, (ii) the use and ownership (subject to Schedule 1.01(b)) of all
----------------
equipment transferred pursuant to Section 1.01 or listed on Schedule 1.01(b) and
----------------
(iii) senior management consultations, in each case as more fully set forth in
the Consulting and Interim Services Agreement.
SECTION 8.03 Sub-Lease. PerSeptive shall, pursuant to and in accordance
----------
with the terms and conditions of the Sub-Lease, subject to obtaining the
landlord's consent, lease the Premises (as defined in the Sub-Lease) to
ChemGenics. ChemGenics shall, pursuant to and in accordance with the terms and
conditions of the Sub-Lease, not be obligated to pay rent until the completion
of the Public Offering; thereafter, ChemGenics shall pay the monthly rent
provided for in the Sub-Lease to PerSeptive. Notwithstanding the foregoing, in
the event PerSeptive's landlord does not consent to the Sublease on a timely
basis, PerSeptive shall provide ChemGenics with satisfactory use of such
premises or equivalent premises on terms equivalent to those set forth in the
Sub-Lease. If the Public Offering does not occur and the asset purchase and
other agreements and instruments set forth herein are rescinded and unwound (as
described below), ChemGenics and PerSeptive agree to negotiate in good faith
regarding the terms and conditions of continuation or termination of the Sub-
Lease, subject to the other terms and provisions thereof.
SECTION 8.04 Standstill; Registration Rights. Except pursuant to the
-------------------------------
Warrant, (i) for a period of ten years after the Closing Date, PerSeptive will
not purchase any Common Stock of ChemGenics (subject to PerSeptive's right to
maintain its pro rata percentage ownership of ChemGenics' capital stock, as more
--- ----
fully set forth in Section 5.06), (ii) for a period of three (3) years after the
Closing Date, PerSeptive will not sell or agree to sell any capital stock of
ChemGenics, during the fourth year will not sell or agree to sell more than
979,268 shares plus up to 10% of the shares actually acquired by PerSeptive upon
exercise of the Warrant, during the fifth year will not sell or agree to sell
more than 1,958,536 shares plus (a) such number of shares
- 30 -
<PAGE>
permitted to be sold in the prior year and not sold and (b) up to an additional
20% of the shares actually acquired by PerSeptive upon exercise of the Warrant,
or in any year thereafter more than 3,427,438 shares plus up to 35% of the
shares actually acquired by PerSeptive upon exercise of the Warrant, provided,
--------
that PerSeptive shall be allowed to transfer shares to subsidiaries or for
accounting purposes as set forth in Exhibit 1.03(C)(iv), (iii) ChemGenics shall
provide PerSeptive with limited "piggy back" and Form S-3 Registration Rights,
and (iv) PerSeptive will enter into the other agreements regarding the capital
stock of ChemGenics, in each case as set forth in the Standstill and
Registration Rights Agreement.
SECTION 8.05 Further Assurances. At any time and from time to time after
------------------
the Closing Date, at the request of ChemGenics and without further
consideration, PerSeptive will execute and deliver such other instruments of
sale, transfer, conveyance, assignment and confirmation as may be reasonably
requested in order to more effectively transfer, convey and assign to ChemGenics
and to confirm ChemGenics' title to the Transferred Assets.
SECTION 8.06 Public Offering. Within a period of 180 days after the
---------------
Closing, ChemGenics will use commercially reasonable efforts to accomplish an
underwritten initial public offering of its Common Stock, in which offering
ChemGenics will attempt to raise between $20 and $30 million (the "Public
Offering"), net to ChemGenics. ChemGenics will seek PerSeptive's consent with
respect to the choice of lead managing underwriter, which consent shall not be
unreasonably withheld. If the Public Offering is not consummated within such
180-day period, the parties may extend the period by mutual agreement. If at
the end of the initial 180-day period, ChemGenics has a registration statement
on file with the SEC, and in ChemGenics' reasonable judgement, there does not
appear to be any material impediment to the successful completion of the Public
Offering, then the period for completing the Public Offering hereunder shall be
automatically extended for an additional 90 days (such 180-day or 270-day
period, as the case may be, is hereinafter collectively referred to as the
"Public Offering Period"). PerSeptive shall at its own cost assist and
cooperate with ChemGenics as ChemGenics may reasonably request in effecting the
Public Offering in a timely manner.
SECTION 8.07 Further Negotiations on Certain Conditions. If (a) the
------------------------------------------
Public Offering Period shall lapse without the successful completion of the
Public Offering, and ChemGenics and PerSeptive shall not have extended the
period by mutual agreement, or (b) if Noubar Afeyan ceases to be available to
consult with ChemGenics pursuant to the Consulting and Interim Services
Agreement prior to completion of the Public Offering, then during the thirty
(30) day period following either such event, the parties shall confer and
negotiate in good faith to seek to agree upon alternate financing arrangements,
or additional agreements and/or modified terms to this Agreement and/or the
other documents executed in connection herewith, to accommodate each party's
respective interests. In the event that the parties do not agree to such
alternate arrangements or additional or modified terms within such thirty (30)
day period, with respect to (a) ChemGenics or PerSeptive and, with respect to
(b), ChemGenics, shall have the right, each in its sole discretion, by giving
written notice to the other party within ninety (90) days following the
expiration of the foregoing thirty (30) day period, to rescind this Agreement,
the other agreements, documents and instruments entered into in connection
herewith, and to unwind the collaboration established by such agreements and
other documents such that: (i) ChemGenics shall return the Transferred Assets
- 31 -
<PAGE>
to PerSeptive in the same condition as the Transferred Assets were delivered,
subject to reasonable wear and tear and consumption of supplies, (ii) PerSeptive
shall return the Shares and the Warrant and any securities issued to PerSeptive
pursuant to Section 5.06 (subject to return of the purchase price paid
therefore) to ChemGenics, (iii) ChemGenics and PerSeptive shall take such other
actions as may be necessary or desirable to restore the respective rights,
obligations and liabilities of ChemGenics and PerSeptive as nearly as possible
to the status quo which existed prior to Closing, subject to the specific
------ ---
provisions of certain of the Exhibits hereto which provide for the continuation
of certain rights and obligations of the parties after the rescission in certain
circumstances, and (iv) return written manifestations of confidential
information (except for such information as is associated with the rights
granted pursuant to Section 9.3 of the License Agreement).
ARTICLE IX
----------
TERMINATION
-----------
SECTION 9.01 Termination. This Agreement may be terminated and the
-----------
transactions contemplated hereby may be abandoned at any time prior to the
Closing:
A. By mutual written consent duly authorized by the Boards of
Directors of ChemGenics and PerSeptive.
B. By ChemGenics or PerSeptive if:
(i) the Closing has not occurred on or prior to June 15, 1996
for any reason other than the breach of any provision of this Agreement by the
party terminating this Agreement;
(ii) the other party materially breaches any of its
representations, warranties or covenants attached hereto; or
(iii) either party is unable in good faith to agree to any
unagreed to material term of one of the other agreements contemplated hereby.
C. By ChemGenics if:
(i) Any of the conditions set forth in Article VI hereof has
not been satisfied on or before June 15, 1996 or shall have become incapable of
fulfillment and shall not have been waived by ChemGenics for any reason other
than a breach by ChemGenics hereunder; or
(ii) If in ChemGenics' good faith judgment there is any
material inaccuracy in any representations or breach of any warranty contained
herein, or any material failure by PerSeptive to perform any commitment,
covenant or condition contained in this Agreement, or there exists any error,
misstatement or omission with regard to any of the Exhibits,
- 32 -
<PAGE>
Schedules or other documents referred to herein, or ChemGenics in its sole
judgment believes that the contents of any of the Exhibits, Schedules,
information or other documents, or the business and condition (financial or
otherwise) of the Drug Discovery Program, frustrates the essential business
purpose of the transaction contemplated herein.
D. By PerSeptive if:
(i) any of the conditions set forth in Article VII hereof has
not been satisfied on or before June 15, 1996 or shall have become incapable of
fulfillment and shall not have been waived by PerSeptive for any reason other
than a breach by PerSeptive hereunder;
(ii) If in PerSeptive's good faith judgment there is any material
inaccuracy in any representations or breach of any warranty contained herein, or
any material failure by ChemGenics to perform any commitment, covenant or
condition contained in this Agreement, or there exists any error, misstatement
or omission with regard to any of the Exhibits, Schedules or other documents
referred to herein, or PerSeptive in its sole judgment believes that the
contents of any of the Exhibits, Schedules, information or other documents, or
the business and condition (financial or otherwise) of ChemGenics, frustrates
the essential business purpose of the transaction contemplated herein.
Upon the occurrence of any of the events specified in this Section 9.01 (other
than paragraph A hereof), written notice of such event shall forthwith be given
to the other party to this Agreement, whereupon this Agreement shall terminate.
SECTION 9.02 Effect of Termination. In the event of the termination and
---------------------
abandonment of this Agreement pursuant to Section 9.01, this Agreement, except
for the provisions of Articles IX and X, shall forthwith become void and be of
no effect, without any liability on the part of any party or its directors,
officers or shareholders. Nothing in this Section 9.02 shall relieve any party
to this Agreement of liability for breach of this Agreement.
ARTICLE X
---------
MISCELLANEOUS
-------------
SECTION 10.01 Notices. All notices, requests, consents and other
-------
communications hereunder shall be in writing, shall be addressed to the
receiving party's address set forth below or to such other address as a party
may designate by notice hereunder, and shall be either (i) delivered by hand,
(ii) made by telex, telecopy or facsimile transmission, (iii) sent by recognized
overnight courier, or (iv) sent by registered or certified mail, return receipt
requested, postage prepaid.
If to ChemGenics:
----------------
Myco Pharmaceuticals Inc.
d/b/a ChemGenics Pharmaceuticals
- 33 -
<PAGE>
One Kendall Square, Building 300
Cambridge, MA 02139
Attn: Barry A. Berkowitz
With a copy to:
Jeffrey M. Wiesen, Esq.
Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
One Financial Center
Boston, MA 02111
If to PerSeptive:
----------------
PerSeptive Biosystems, Inc.
500 Old Connecticut Path
Framingham, MA 01701
Attn: Noubar B. Afeyan
With a copy to:
Rufus C. King, Esq.
Testa, Hurwitz & Thibeault, LLP
125 High Street
Boston, MA 02110
All notices, requests, consents and other communications hereunder shall be
deemed to have been delivered (i) if by hand, at the time of the delivery
thereof to the receiving party at the address of such party set forth above,
(ii) if made by telex, telecopy or facsimile transmission, at the time that
receipt thereof has been acknowledged by electronic confirmation or otherwise,
(iii) if sent by overnight courier, on the next business day following the day
such notice is delivered to the courier service, or (iv) if sent by registered
or certified mail, on the fifth business day following the day such mailing is
made.
SECTION 10.02 Entire Agreement. This Agreement together with the Exhibits
----------------
and Schedules hereto and the other documents executed in connection herewith
(together, the "Documents") embodies the entire agreement and understanding
between the parties hereto with respect to the subject matter hereof and
supersedes all prior oral or written agreements and understandings relating to
the subject matter hereof except for the Confidentiality Agreement, which shall
remain in effect in accordance with its terms. No statement, representation,
warranty, covenant or agreement of any kind not expressly set forth in the
Documents shall affect, or be used to interpret, change or restrict, the express
terms and provisions of this Agreement.
- 34 -
<PAGE>
SECTION 10.03 Modifications and Amendments. The terms and provisions of
----------------------------
this Agreement may be modified or amended only by written agreement executed by
all parties hereto.
SECTION 10.04 Waivers and Consents. No failure or delay by a party hereto
--------------------
in exercising any right, power or remedy under this Agreement, and no course of
dealing between the parties hereto, shall operate as a waiver of any such right,
power or remedy of the party. No single or partial exercise of any right, power
or remedy under this Agreement by a party hereto, nor any abandonment or
discontinuance of steps to enforce any such right, power or remedy, shall
preclude such party from any other or further exercise thereof or the exercise
of any other right, power or remedy hereunder. The election of any remedy by a
party hereto shall not constitute a waiver of the right of such party to pursue
other available remedies. No notice to or demand on a party not expressly
required under this Agreement shall entitle the party receiving such notice or
demand to any other or further notice or demand in similar or other
circumstances or constitute a waiver of the rights of the party giving such
notice or demand to any other or further action in any circumstances without
such notice or demand. The terms and provisions of this Agreement may be
waived, or consent for the departure therefrom granted, only by written document
executed by the party entitled to the benefits of such terms or provisions. No
such waiver or consent shall be deemed to be or shall constitute a waiver or
consent with respect to any other terms or provisions of this Agreement, whether
or not similar. Each such waiver or consent shall be effective only in the
specific instance and for the purpose for which it was given, and shall not
constitute a continuing waiver or consent.
SECTION 10.05 Assignment. Neither this Agreement, nor any right
----------
hereunder, may be assigned by any of the parties hereto without the prior
written consent of the other parties.
SECTION 10.06 Parties in Interest. This Agreement shall be binding upon
-------------------
and inure solely to the benefit of each party hereto and their permitted
assigns, and nothing in this Agreement, express or implied, is intended to
confer upon any other person any rights or remedies of any nature whatsoever
under or by reason of this Agreement. Nothing in this Agreement shall be
construed to create any rights or obligations except among the parties hereto,
and no person or entity shall be regarded as a third-party beneficiary of this
Agreement.
SECTION 10.07 Governing Law. This Agreement and the rights and
-------------
obligations of the parties hereunder shall be construed in accordance with and
governed by the internal laws of the Commonwealth of Massachusetts, without
giving effect to the conflict of law principles thereof.
SECTION 10.08 Arbitration.
-----------
(a) The Parties shall attempt to resolve any dispute or controversy arising
under or relating to the interpretation or meaning of this Agreement by good
faith negotiations. Any matter that cannot be resolved by such good faith
negotiation shall be resolved by final and binding arbitration conducted by
three (3) arbitrators in Boston, Massachusetts, in accordance with the then-
current American Arbitration Association ("AAA") Commercial Arbitration Rules
---
(the "AAA Rules") as modified by this Section 10.08
---------
- 35 -
<PAGE>
(b) The arbitrators shall be selected by mutual agreement of the parties
or, failing such agreement, in accordance with the aforesaid AAA Rules. At
least one (1) of the arbitration panel shall be reasonably familiar with the
biotechnology industry. The parties shall bear the costs of the arbitrators
equally. No arbitrator may be affiliated in any way with either party.
(c) The parties shall have the right of limited pre-hearing discovery, in
accordance with the U.S. Federal Rules of Civil Procedure, as then in effect,
for a period not to exceed sixty (60) days.
(d) As soon as the discovery is concluded, but in any event with thirty
(30) days thereafter, the arbitrators shall hold a hearing in accordance with
the AAA Rules. Thereafter, the arbitrators shall promptly render a written
decision, together with a written opinion setting forth in reasonable detail the
grounds for such a decision.
(e) Judgment may be entered in any court of competent jurisdiction to
enforce the award entered by the arbitrator.
(f) The duty of the parties to arbitrate any dispute hereunder shall
survive expiration or termination of this Agreement for any reason.
SECTION 10.09 Jurisdiction and Service of Process. Subject to the terms
-----------------------------------
of Section 10.08, any legal action or proceeding with respect to this Agreement
may be brought in the courts of the Commonwealth of Massachusetts or of the
United States of America for the District of Massachusetts. By execution and
delivery of this Agreement, each of the parties hereto accepts for itself and in
respect of its property, generally and unconditionally, the jurisdiction of the
aforesaid courts. The parties hereby irrevocably waive any objection or defense
that they may now or hereafter have to the assertion of personal jurisdiction by
any such court in any such action or to the laying of the venue of any such
action in any such court, and hereby waive, to the extent not prohibited by law,
and agree not to assert, by way of motion, as a defense, or otherwise, in any
such proceeding, any claim that it is not subject to the jurisdiction of the
above-named courts for such proceedings. Each of the parties hereto irrevocably
consents to the service of process of any of the aforementioned courts in any
such action or proceeding by the mailing of copies thereof by registered mail,
postage prepaid, to the party at its address set forth in Section 10.01 hereof
and irrevocably waive any objection or defense that it may now or hereafter have
to the sufficiency of any such service of process in any such action. Nothing
in this Section 10.08 shall affect the rights of the parties to commence any
such action in any other forum or to serve process in any such action in any
other manner permitted by law.
SECTION 10.10 Severability. In the event that any court of competent
------------
jurisdiction shall finally determine that any provision, or any portion thereof,
contained in this Agreement shall be void or unenforceable in any respect, then
such provision shall be deemed limited to the extent that such court determines
it enforceable, and as so limited shall remain in full force and effect. In the
event that such court shall determine any such provision, or portion thereof,
wholly unenforceable, the remaining provisions of this Agreement shall
nevertheless remain in full force and effect.
- 36 -
<PAGE>
SECTION 10.11 Interpretation. The parties hereto acknowledge and agree
--------------
that: (i) each party and its counsel reviewed and negotiated the terms and
provisions of this Agreement (except with respect to the disclosure schedules
regarding the Drug Discovery Program which are the sole responsibility of
PerSeptive) and have contributed to its revision; (ii) the rule of construction
to the effect that any ambiguities are resolved against the drafting party shall
not be employed in the interpretation of this Agreement; and (iii) the terms and
provisions of this Agreement shall be construed fairly as to all parties hereto
and not in favor of or against any party, regardless of which party was
generally responsible for the preparation of this Agreement.
SECTION 10.12 Headings and Captions. The headings and captions of the
---------------------
various subdivisions of this Agreement are for convenience of reference only and
shall in no way modify, or affect, or be considered in construing or
interpreting the meaning or construction of any of the terms or provisions
hereof.
SECTION 10.13 Enforcement. Each of the parties hereto acknowledges and
-----------
agrees that the rights acquired by each party hereunder are unique and that
irreparable damage would occur in the event that any of the provisions of this
Agreement to be performed by the other party were not performed in accordance
with their specific terms or were otherwise breached. Accordingly, in addition
to any other remedy to which the parties hereto are entitled at law or in
equity, each party hereto shall be entitled to an injunction or injunctions to
prevent breaches of this Agreement by the other party and to enforce
specifically the terms and provisions hereof in any federal or state court to
which the parties have agreed hereunder to submit to jurisdiction.
SECTION 10.14 Reliance. The parties hereto agree that, notwithstanding
--------
any right of any party to this Agreement to investigate the affairs of any other
party to this Agreement, the party having such right to investigate shall have
the right to rely fully upon the representations and warranties of the other
party expressly contained in this Agreement and on the accuracy of any Schedule,
Exhibit or other document attached hereto or referred to herein or delivered by
such other party or pursuant to this Agreement.
SECTION 10.15 Survival, Etc. All of the representations and warranties set
--------------
forth in this Agreement shall survive the Closing and shall terminate as of the
earliest of (i) the recision of this Agreement in accordance with Section 8.08,
(ii) the effective date of the registration statement with respect to the Public
Offering described in Section 8.07, and (iii) one year after the date hereof.
No claim shall be made based upon such representations and warranties on or
after such date. The sole remedy for breach of any of the representations and
warranties shall be compensation for damages actually and reasonably incurred by
the party harmed by the breach thereof. In no event shall either party be
liable to the other for any consequential damages as a result of the breach of
any representation or warranty set forth in this Agreement.
SECTION 10.16 Expenses. Each of the parties hereto shall pay its own fees
--------
and expenses (including the fees of any attorneys, accountants, appraisers or
others engaged by such party) in connection with this Agreement and the
transactions contemplated hereby whether or not the transactions contemplated
hereby are consummated.
- 37 -
<PAGE>
SECTION 10.17 No Broker or Finder. Each of the parties hereto represents
-------------------
and warrants to the other that no broker, finder or other financial consultant
has acted on its behalf in connection with this Agreement or the transactions
contemplated hereby in such a way as to create any liability on the other. Each
of the parties hereto agrees to indemnify and save the other harmless from any
claim or demand for commission or other compensation by any broker, finder,
financial consultant or similar agent claiming to have been employed by or on
behalf of such party and to bear the cost of legal expenses incurred in
defending against any such claim.
SECTION 10.18 Publicity. No party shall issue any press release or
---------
otherwise make any public statement with respect to the execution of, or the
transactions contemplated by, this Agreement without the prior written consent
of the other party, except as may be required by law. Prior to making any
public disclosure required by the rules and regulations of the Securities and
Exchange Commission, the disclosing party shall give the other parties a copy of
the proposed disclosure and reasonable opportunity to comment on the same.
SECTION 10.19 Counterparts. This Agreement may be executed in one or more
------------
counterparts, and by different parties hereto on separate counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.
[REMAINDER OF PAGE BLANK; SIGNATURE PAGE FOLLOWS]
- 38 -
<PAGE>
IN WITNESS WHEREOF, ChemGenics and PerSeptive have executed this Agreement
as of the day and year first above written.
ATTEST: MYCO PHARMACEUTICALS INC., d/b/a
CHEMGENICS PHARMACEUTICALS
/s/ William Timberlake By: /s/ Barry A. Berkowitz
- ---------------------------- ------------------------------
Barry A. Berkowitz
President
ATTEST: PERSEPTIVE BIOSYSTEMS, INC.
/s/ Samuel P. Hunt, III By: /s/ Noubar B. Afeyan
- ---------------------------- ------------------------------
Noubar B. Afeyan
President
- 39 -
